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A B S T R A C T   
Fundus-controlled perimetry (FCP, also called ‘microperimetry’) allows for spatially-resolved mapping of visual 
sensitivity and measurement of fixation stability, both in clinical practice as well as research. The accurate spatial 
characterization of visual function enabled by FCP can provide insightful information about disease severity and 
progression not reflected by best-corrected visual acuity in a large range of disorders. This is especially important 
for monitoring of retinal diseases that initially spare the central retina in earlier disease stages. Improved intra- 
and inter-session retest-variability through fundus-tracking and precise point-wise follow-up examinations even 
in patients with unstable fixation represent key advantages of these technique. The design of disease-specific test 
patterns and protocols reduces the burden of extensive and time-consuming FCP testing, permitting a more 
meaningful and focused application. Recent developments also allow for photoreceptor-specific testing through 
implementation of dark-adapted chromatic and photopic testing. A detailed understanding of the variety of 
available devices and test settings is a key prerequisite for the design and optimization of FCP protocols in future 
natural history studies and clinical trials. Accordingly, this review describes the theoretical and technical 
background of FCP, its prior application in clinical and research settings, data that qualify the application of FCP 
as an outcome measure in clinical trials as well as ongoing and future developments.   
1. Introduction 
Scientific and engineering developments in the past five decades 
provide us today with fundus-controlled perimetry (FCP, also called 
‘microperimetry’) devices, allowing for feasible measurement of visual 
sensitivity and fixation stability in clinical practice and research. Pre-
vious manuscripts have described the diversity of applications to better 
screen for, diagnose and follow retinal diseases. However, a detailed 
explanation of the psychophysical and psychometric foundations 
underlying FCP, systematic classification of previous clinical findings 
and identification of areas that warrant further consideration are lacking 
in the current literature. In the present work, we review and describe 
FCP technology (1. History and devices, 2. Theoretical and technical 
background), its use in a clinical and research setting (3. Fixation and its 
examination, 4. Previous applications in studies), mode of application (5. 
Best practices) and next steps in its development and future use (6. Future 
directions). 
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1.1. Terminology 
Whilst FCP (or fundus, fundus-driven perimetry) is commonly 
referred to as “microperimetry”, it must be noted that the stimulus sizes 
typically used are identical to stimuli applied in standard automated 
perimetry (Rohrschneider et al., 2008). Here, we use the term 
fundus-controlled perimetry (“FCP”) as originally suggested (Kani and 
Ogita, 1979). 
1.2. History 
1.2.1. First description of the concept 
In 1851, Hermann von Helmholtz not only revolutionized the field of 
ophthalmology with the invention of the ophthalmoscope, but he also 
provided the first description of FCP in the very same publication 
(Helmholtz, 1851). Using the ophthalmoscope both as viewing system to 
track the fundus and its inherent light as stimulus, von Helmholtz 
demonstrated that the optic nerve head does indeed correspond with a 
scotoma (Helmholtz, 1851). Based on this seminal observation, von 
Helmholtz concluded that visual phototransduction must inevitably 
occur prior to the optic nerve (Helmholtz, 1851). 
1.2.2. History of visual field testing 
Subsequent developments of clinical visual field testing have laid the 
foundation for today’s standard automated perimetry as well as FCP. 
The clinical relevance of peripheral and central visual field testing was 
underscored by Albrecht von Graefe in 1856 in a hallmark publication 
that described in detail many clinical phenotypes of visual field loss 
including glaucomatous visual field loss, concentric visual field defects 
in retinitis pigmentosa, as well as paracentral ring scotomas in macular 
diseases and their implications for activities of daily living (v. Graefe, 
1856). Soon after, Aubert and Förster laid the foundation for quantita-
tive visual field testing using initially a tangent screen (Aubert and 
Foerster, 1857), and later by introducing the Förster (arc) perimeter to 
ensure a constant visual angle of the stimulus (Förster, 1869). The 
clinical importance of the central visual field and relative scotomas was 
highlighted in 1889 by Jannik Bjerrum. In his landmark paper on the 
diagnosis of glaucoma, he used a tangent screen and small ivory 
test-objects of variable size (Bjerrum, 1889). Ferree and Rand identified 
key determinates of differential light sensitivity and measurement 
reproducibility (Ferree and Rand, 1922), that provided the basis for the 
development of the Goldmann bowl perimeter (Goldmann, 1945, 1946). 
Standards set by this device including stimulus sizes and background 
illumination level for photopic testing were adapted for today’s 
commercially-available FCP devices. Earlier, Louise Sloan introduced 
the method of static perimetry as part of a comprehensive four-part 
discourse on clinical perimetry (Sloan, 1940), which led to the devel-
opment of the Tübinger perimeter of Harms and Aulhorn designed for 
static perimetry in 1955 (Aulhorn and Harms, 2015). Further key de-
velopments were the automation of static perimetry (Heijl and Krakau, 
1975; Spahr and Fankhauser, 1974), the introduction of visual field 
indices for the mathematical description of test results (Flammer et al., 
1985; Heijl et al., 1987a), and the adoption of reliability measures 
including quantification of fixation losses (Heijl and Krakau, 1975) as 
well as false-positive or negative catch trials (Heijl et al., 1987b). 
1.2.3. History of FCP 
Similar to von Helmholtz’s experiment, clinicians started doc-
umenting retinal sensitivity while examining the fundus (Meyers, 1959; 
Trantas, 1955; Watzke and Allen, 1969). In 1977, two devices were 
presented at the “Second International Visual Field Symposium” enabling 
FCP, however without automated fundus-tracking (Kani, 1977; Tagami 
and Isayama, 1977). A subsequent key development has been the in-
vention of the scanning laser ophthalmoscope (Webb and Hughes, 
1981), which facilitates high contrast imaging of the retina and was soon 
shown to be useful for FCP (Timberlake et al., 1982). Sunness and 
coworkers modified a fundus-camera to perform dark-adapted FCP 
(Sunness et al., 1988, 1987). Further key innovations toward clinically 
applicable FCP were the development of software for static threshold 
testing across multiple test-points (Rohrschneider et al., 1995b), and the 
introduction of fundus-tracking to enable point-by-point correlation and 
minimize the intra- and inter-session retest-variability through accurate 
stimulus placement (Sunness et al., 1995). 
1.3. Commercially available instruments 
The first commercially available device enabling FCP was the scan-
ning laser ophthalmoscope 101 (SLO 101, Rodenstock Instrumente 
GmbH, Ottobrunn-Riemerling, Germany) presented at the “Ninth Inter-
national Visual Field Symposium” (Plesch and Klingbeil, 1989; Stürmer 
et al., 1991). It projects a Helium–Neon laser beam (632.8 nm) and 
infrared diode laser (780 nm) concurrently on the fundus with a field 
size of 33 ◦ × 21 ◦. The HeNe-laser served as light source for the back-
ground illumination and stimulus presentation. While the SLO 101 
permitted the presentation of variegated stimulus patterns in principle, 
it only allowed for presentation of red stimuli and the original Roden-
stock software was insufficient for clinical use. This led to the devel-
opment of multiple custom software solutions (Rohrschneider et al., 
1995b). 
The Micro Perimeter 1 (MP-1, NIDEK Technologies Srl, Padova, 
Italy) was the first commercially available device dedicated primarily to 
FCP. An infrared fundus camera (45◦ field of view) serves for imaging, 
while stimuli and the background are projected by a liquid crystal 
display (LCD) for mesopic testing (Midena et al., 2004; Springer et al., 
2005). Moreover, its sophisticated software encompasses eye-tracking at 
a frequency of 25 Hz, allows for follow-up examinations, and offers the 
ability to (easily) customize the test-grid as well as test-parameters such 
as the stimulus size, duration and color. In 2011, Crossland and col-
laborators described a modification allowing for scotopic testing with 
the MP-1 (Crossland et al., 2011b), which led to the commercialization 
of the MP-1S featuring the addition of a neutral density filter and 
short-pass filter to the optical path. The device also allows for 
non-mydriatic color fundus photography. Disadvantages of the MP-1 
device were the limited dynamic range of the liquid crystal display, 
which results in a marked ceiling effect in normal subjects or patients 
with mild functional loss (Bowl et al., 2013), and long testing duration in 
patients with poor fixation or large scotomas. For scotopic testing with 
the MP-1S, a “filter-selection-test” is necessary to select an appropriate 
neutral density filter in consideration of the limited dynamic range 
(Steinberg et al., 2017). Further, the threshold measurements along the 
vertical meridian were reported to be incompatible with the established 
hill-of-vision (Springer et al., 2005). Moreover, the IR-camera image 
quality is suboptimal. The device (now replaced by the MP3 device, cf. 
below) was nevertheless a major step forward and has been used in 
various large-scale multicenter trials (Holz et al., 2018). 
The OCT/SLO microperimeter (Optos plc, Dunfermline, U.K. [pre-
viously OPKO Instrumentation, Miami, FL]) represent another FCP de-
vice that is no longer commercially available. The unit performs optical 
coherence tomography, scanning laser ophthalmoscopy and FCP. The 
system uses an organic light-emitting diode (OLED) screen to present 
stimuli on a photopic background (10 cd/m2). While this instrument 
facilitates structure function correlation, the limited dynamic range of 
20 dB impacts its clinical applicability (Liu et al., 2014). 
The Macular Integrity Assessment device (MAIA, CenterVue S.p.A., 
Padova, Italy) addressed technical limitation in tracking, image quality 
and dynamic range of earlier devices. Its SLO system provides a high 
image quality for fundus-tracking (and for subsequent structure function 
correlation). For stimulus presentation, the MAIA uses a light emitting 
diode (LED) and provides a dynamic range of 36 dB for mesopic testing 
(background 1.27 cd/m2). No ceiling effect is present for this instrument 
and the sensitivity profiles in healthy subjects match the established 
photoreceptor distribution (Pfau et al., 2017a). The S-MAIA (Scotopic 
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Macular Integrity Assessment, CenterVue) device enabling dark-adapted 
two-color testing with an additional cyan and red LED has been devel-
oped subsequently (Pfau et al., 2017a). The dynamic range for 
dark-adapted testing has been extended from initially 20 dB–36 dB for 
the final version of the S-MAIA device (Pfau et al., 2020c). While the 
S-MAIA provides both scotopic and mesopic testing, none of the MAIA 
devices allow for photopic testing. 
Similar to the MP-1, the MP-3 (NIDEK CO., Ltd., Gamagori, Japan) 
uses, an infrared fundus camera for tracking and an LCD projector for 
stimulus presentation. This projector allows for both mesopic (1.27 cd/ 
m2) and photopic (10 cd/m2) testing and features a dynamic range of 34 
dB ensuring the absence of a ceiling effect. A scotopic version of the 
device is now also available (NIDEK MP-3 Type S). The MP-3 also allows 
for high-resolution, non-mydriatic color funds photography and features 
the highest tracking speed of the commercially-available devices (30 
Hz). 
The Compass (CenterVue) also allows for photopic (background of 
10 cd/m2) FCP with a testing field of up to 60◦. The device is based on a 
SLO system for fundus-tracking and uses an LED to project the stimuli. 
In addition to commercially available devices, custom built devices 
have been designed by various research groups to answer specific 
research questions. This includes adaptive-optic (AO) FCP devices 
allowing for single-cell psychophysics (Harmening et al., 2014). 
2. Theoretical and technical background 
2.1. Psychophysics and fundamentals of perimetry 
The theoretical framework underlying FCP is largely based on stan-
dard automated perimetry and fundamental psychophysical principles. 
However, some factors such as the fundus-tracking and the Maxwellian 
view setup are unique to FCP. This section provides the fundamental 
principles that also govern the provided best-practice recommendation 
below (cf. 5. Best practices). 
2.1.1. 2.1.1 Wb’s law, Fechner’s law and the decibel scale 
The decibel scale employed in FCP has its foundation in Weber’s law 
and Fechner’s law. The general relationship between the initial intensity 
of a given stimulus (e.g. luminance in the case of light) and the smallest 
detectable increment was formalized by Weber. According to Weber’s 
law, the just-noticeable difference (JND), the smallest change in stim-
ulus (ΔL) that can be perceived, is proportional to the initial stimulus 




Based on the assumption that Weber’s law holds (i.e., the JND is a 
constant fraction of the stimulus), and that the JND is the basic unit of 
perceived magnitude (all JND steps are perceptually equal to each 
other), Fechner’s law stated that the subjective sensation is proportional 
to the logarithm of the stimulus intensity. For visual field testing, the 
logarithmic unit decibel (dB) has been adapted to express the threshold 
differential luminance (ΔL = LThreshold − LBackground) in relation to the 
instrument-specific maximum stimulus luminance (Lmax). It is defined 
according to the International Organization for Standardization (ISO 
12866:1999) as:  
ΔS (in dB)= 10 × log 10
Lmax
ΔL 
Therefore, 0 dB denotes the brightest stimulus a device can display. 
Each 1 dB increment corresponds to an attenuation of the stimulus 
luminance by a factor of 1.26, while 3 dB corresponds approximately to 
an attenuation factor of 2-fold and 10 dB corresponds to an attenuation 
factor of 10-fold. Due to the logarithmic scaling, decibel values between 
different devices (with the same background luminance) are theoreti-
cally convertible by simple addition or subtraction of a constant if the 
maximum stimulus luminance (i.e., luminance of 0 dB stimulus) differs 
(cf. Supplementary Table S1 and 2.4.3 Inter-device reliability). 
2.1.2. Differential luminance sensitivity or threshold luminance 
The response probability in dependence of the stimulus intensity is a 
continuous, monotonous function. It may be described by the psycho-
metric function relating stimulus intensity to response probability of 
sigmoid shape. Hereby, the differential luminance sensitivity (DLS, or 
threshold luminance) is defined as the stimulus intensity corresponding 
to a response probability of 50% (Schiefer et al., 2005). 
2.1.3. 2.1.3 Static perimetry and threshold (staircase) strategies 
In static perimetry, the retinal sensitivity is probed at fixed test- 
points as defined by the perimetry test-pattern. Various threshold stra-
tegies may be used for static perimetry testing including strategies such 
as the 4-2 staircase strategy. These aim to identify the threshold at which 
a stimulus has a 50% probability of being detected. The accuracy and 
test duration of staircase strategies is dependent on the start point, step- 
sizes and number of reversals (Schiefer et al., 2005). A further group of 
adaptive strategies commonly encountered in non-fundus controlled 
static perimetry are Bayesian and maximum-likelihood procedures. 
Today, the COMPASS device is the only commercially available 
fundus-controlled device that offers such a threshold strategy (ZEST). 
A special case is supra-threshold testing with a fixed stimulus in-
tensity. While supra-threshold testing is not informative of the 
threshold, it may be applied to map scotomas in a very time-efficient 
manner (Wu et al., 2019a). 
2.1.4. 2.1.4 Kinetic perimetry 
Kinetic perimetry is an alternative method of perimetry. Hereby, 
stimuli are moved along a trajectory (termed vector) from areas of non- 
seeing to seeing until a response is recorded. Compared to static peri-
metry, this approach is more time-efficient for the assessment of the 
peripheral visual field, which is irrelevant in the setting of FCP due to 
the limited testing and imaging field. A second potential advantage is the 
possibility to map scotomas with high spatial-resolution. The SLO 101 
(with custom software) and the MP-1 devices allow for automated ki-
netic perimetry while imaging the fundus (Rohrschneider et al., 2008, 
1995a). However, to our knowledge, kinetic perimetry has not been 
applied in the setting of FCP study since. 
2.1.5. 2.1.5 temporal summation and stimulus duration 
Bloch’s law states that the visual threshold is proportional to the 
product of the stimulus luminance and duration and applies up to a 
critical time (approximately 100 ms). In commercially available FCP 
devices, the stimulus duration is typically 200 ms and therefore beyond 
the temporal integration time. This ensures that minor inaccuracies in 
the duration of stimulus presentation do not affect threshold measure-
ments. Stimulus durations longer than 200 ms, which is a possible 
setting for the MP-1 device, are generally not advisable given that the 
initiation of saccades to an unexpected stimulus takes about 200 ms 
(Fuchs, 1967). 
2.1.6. 2.1.6 Spatial summation and stimulus size 
Ricco’s law states that the ratio of the stimulus luminance and 
angular area of a stimulus required for detection are constant for small 
targets that are within the receptive field of a single retinal ganglion cell 
(e.g., the Goldmann I and II stimuli) (Khuu and Kalloniatis, 2015a). For 
stimuli larger than the critical area (Ricco’s area), Piper’s law applies 
stating that ratio of the stimulus luminance and square-root of the 
angular area required for detection are constant (Khuu and Kalloniatis, 
2015a). In optic neuropathies such as glaucoma, stimuli scaled to the 
size of Ac may be optimal to detect drop-out by small numbers of gan-
glion cells (Anderson, 2006; Khuu and Kalloniatis, 2015b). Nevertheless, 
stimuli larger than the critical area are often applied clinically to 
monitor glaucoma in consideration of the dynamic range and 
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repeatability (Khuu and Kalloniatis, 2015b; Wall et al., 2010). These 
aspects have not been studied in detail in the context of FCP and macular 
diseases to date. 
In FCP, typically Goldmann III stimuli (diameter of 0.43◦) are used 
across devices, which are larger than the critical area in the central 
retina of healthy observers under photopic conditions (Anderson, 2006). 
For scotopic testing with the MP-1S device, Goldmann V stimuli 
(diameter of 1.72◦) have previously been applied (Steinberg et al., 
2017), which are also larger than the critical area for scotopic conditions 
in healthy observers (Anderson, 2006; Redmond et al., 2010). 
2.1.7. 2.1.7 Reliability indices 
Multiple indices have been proposed to predict the reliability of a 
given examination (cf. with 2.4 Retest-reliability below). In standard 
automated perimetry, the quantification of so-called “fixation losses” 
(Heijl–Krakau “fixation catch-trial errors”) is done by presenting stimuli 
to the blind spot (Heijl and Krakau, 1975). In FCP, this method has also 
been integrated – however, due to fundus-tracking, this measurement 
represents not a true measure of fixation loss (despite of the name), but 
rather a false-positive catch trial (assuming accurate selection of the 
optic disc by the operator, no head tilt bringing the supposed blind spot 
into view, and sufficiently accurate fundus-tracking). Further, these 
catch-trials are typically presented at a low frequency (approximately 
1/min). The estimate of these false positive responses might be impre-
cise due to the low sampling rate (i.e., the measured rate of “fixation 
losses” is likely to deviate from the true false-positive response rate for 
any given patient). 
Another measure of patient reliability adopted from standard auto-
mated perimetry is the rate of wrong-press events (Olsson et al., 1997). 
These are defined as response button press events outside of the tem-
poral response window, which the MAIA device records. The last gen-
eration of devices (COMPASS and MP-3) also offer conventional 
false-negative and false-positive catch trials. 
For FCP, multiple groups have proposed the use of cut-off values for 
false-positive responses to stimuli to the optic nerve head of 25% (Wu 
et al., 2016a). Yet, factors related to the disease severity (e.g., mean 
sensitivity) appear to have an even greater influence on the 
retest-reliability (von der Emde et al., 2019b). There is continued in-
terest in using fixation parameters as well as consideration of the test 
duration for the assessment of reliability and this is still under investi-
gation (Yohannan et al., 2017). 
2.1.8. 2.1.8 Dynamic range, ceiling and floor effects 
A major limitation of the first commercially available FCP devices is 
the limited dynamic range that can lead to false conclusions in the 
interpretation of test results. For FCP application, it is essential to 
consider the physical dynamic range (range of the dimmest to the 
brightest presentable stimulus) of the device with regards to ceiling as 
well as floor effects. While ceiling effects impair the ability to detect 
mild loss in retinal sensitivity, residual retinal sensitivity might not be 
detected because of floor effects. Of note, the physiological range of 
retinal sensitivity is higher for rod as compared to cone function. Finally, 
it is important to consider the limited dynamic range in relation to the 
test-retest variability. For the MP-1 device, the physical dynamic range 
of 20 dB (using Goldmann III stimuli) was indeed shown to be insuffi-
cient to resolve normal retinal sensitivity and therefore also mild func-
tional loss (Bowl et al., 2013). In contrast, no ceiling effect is evident for 
the MAIA, the COMPASS and the MP-3 device, highlighting the 
comparative advantage of these devices for the detection of mild func-
tional loss (Pfau et al., 2017a). 
2.2. Unique characteristics of FCP 
2.2.1. Fundus-tracking 
The key feature of FCP is the ability to present stimuli at specific 
retinal locations enabled by continuous visualization of the retina 
throughout and between examinations (Fig. 1). This allows for (i.) 
testing of retinal sensitivity in patients without stable fixation, (ii.) 
repeated testing at the same location to improve the intra- and inter- 
session reliability, which enhances longitudinal comparability of re-
sults, as well as (iii.) precise structure function correlation. Precise data 
on the in vivo tracking performance (especially of the devices in com-
parison to each other) is unfortunately not available. While manufac-
turers typically report the frequency of eye tracking, it is unclear how 
this translates to accuracy in stimulus presentation. For the MP-1 device, 
it was shown in an ex vivo setting that the time difference between 
movement of a tracking feature (simulating a saccade) and the corre-
sponding onset of stimulus movement was 83 ± 12 ms (Cideciyan et al., 
2016). In conjunction with eye movement data, the authors estimated 
that such a delay would result in an average absolute displacement error 
of <0.25◦ in patients lacking foveal fixation (end-stage retina-wide 
photoreceptor degeneration) (Cideciyan et al., 2016). 
Overall, the retest-reliability appears to be more uniform (i.e., less 
heteroscedastic) compared to standard automated perimetry (SAP) 
(Pfau et al., 2017b). However, studies comparing FCP with and without 
activated fundus-tracking are lacking. Further, heteroscedasticity has 
been reported in patients with glaucoma (Wu et al., 2016b), Stargardt 
disease (Pfau et al., 2020b) as well as age-related macular degeneration 
(Barboni et al., 2018). Further, lower retest-reliability has been reported 
at the boundary of the optic nerve head as a model for deep scotomas 
(Wu et al., 2015b) and within areas of high local gradients of sensitivity 
(e.g. the location between a region of normal and markedly reduced 
sensitivities) (Wu et al., 2016b), with high spatial density testing. Whilst 
a direct comparison with non-fundus controlled perimetry has not been 
performed, the measurement variability for regions with severe loss of 
function are likely to be much lower with FCP. 
2.2.2. Maxwellian view versus natural viewing optical systems 
FCP devices employ typically a Maxwellian view setup in contrast to 
standard automated perimetry (Midena and Pilotto, 2013), which means 
that the illumination source is made optically conjugate to the pupil of 
the eye (Burns and Webb, 1995). This leads to important implications 
with regard to the effect of pupil size on threshold determinations. In 
standard automated perimetry, the retinal illumination can vary 
depending on the pupil diameter and lenticular opacification. However, 
since the background and stimulus are equally affected by these varia-
tions and since Weber’s law holds under photopic conditions, the 
thresholds remain identical (Aulhorn et al., 1966). In contrast, for 
mesopic testing, minor reductions in light transmission may affect the 
measured thresholds (Klewin and Radius, 1986). 
On the other hand, due the Maxwellian view setup of FCP, pupil size 
is not expected to affect threshold determinations even under mesopic 
conditions, since the pupil size required by the devices is designed to be 
smaller than the typical size of the human pupil. The absence of an effect 
of pupil dilatation has been experimentally confirmed for the MAIA 
device (Han et al., 2017). However, defocus and decentration due to 
clipping of the stimulus by the iris may affect the test results (cf. Fig. 3). 
2.3. Photoreceptor specificity and dark-adapted testing 
Isolation techniques for perimetry testing have been established, that 
take advantage of the differential spectral sensitivity of the S-, L/M-cone 
and rod photoreceptors (Fig. 2). Hereby, relative photoreceptor function 
isolation may be achieved through optimization of the stimulus and 
background. Importantly, photoreceptor function isolation is indis-
pensable (i.) to measure functional loss or potential treatment effects in 
a specific and hypothesis-driven manner and (ii.) to avoid “redundancy” 
of target detection leading to insensitivity to potentially photoreceptor- 
specific lesions (Simunovic et al., 2016). However, mesopic 
white-on-white testing is the most common test condition used in FCP, 
which maximizes the redundancy of target detection (Simunovic et al., 
2016). Instead of a psychophysical rationale, the choice of a mesopic 
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background illumination of the MP-1 device appears to be linked to the 
highest practical illumination level with regard to the dynamic range of 
the built-in liquid crystal display. 
Dark-adapted (DA, scotopic) testing presumably allows for probing 
relative rod compared to cone photoreceptor function using a single 
stimulus close to the peak of the scotopic sensitivity function. This is 
achieved with the MP-1S by incorporating a neutral density filter and a 
short-pass filter to the optical path (Crossland et al., 2011b). However, 
due to the limited dynamic range of the MP-1S, the neutral density filter 
must be adjusted depending on the degree of sensitivity loss of the pa-
tient (Steinberg et al., 2015). Further, this single stimulus technique 
does not allow documentation of the photoreceptor source, when rod 
sensitivities are reduced below normal DA cone sensitivities (McGuigan 
et al., 2016). The now available MP-3 Type S features a much greater 
dynamic range and therefore does not require a patient-specific selec-
tion of neutral density filters. 
Fig. 1. FCP devices.  
Fig. 2. Selective perimetry strategies.  
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Fig. 3. Best-practice recommendations.  
Table 1 


























SLO 101 (and 
SLO 102) 


















(488 nm and 
514 nm) 






































2009 CenterVue SLO - IR n/a 36◦ 0–36 dB 25 Hz 1.27 cd/m2 318 cd/m2 White LED 
(with two 
peaks) 
•S-MAIA 2017 CenterVue SLO - IR n/a 36◦ 0–36 dB 25 Hz n/a 2.54 scot. 
cd/m2 
Cyan LED 
(max. 505 nm) 
Red LED (627 
nm) 




























at 500 nm 
(FWHM of 20 
nm) 
COMPASS 2015 CenterVue SLO 
fundus 
imaging 





M. Pfau et al.                                                                                                                                                                                                                                    
Progress in Retinal and Eye Research 82 (2021) 100907
7
Dark-adapted two-color testing with cyan and red stimuli provides 
the ability to document the photoreceptor source of the measured 
thresholds based on the specific sensitivity difference (Ernst et al., 1983; 
Jacobson et al., 1986). The S-MAIA device implements this principle in 
the setting of FCP (Pfau et al., 2017a). However, the dynamic range of 
the current version of the device is limited effectively to 23 dB in 
consideration of the normal function (i.e., limits of perception), despite 
of the 36 dB physical dynamic range for DA testing allowing to present 
even dimmer stimuli (Pfau et al., 2020c). 
Cone isolation can be achieved through photopic (10 cd/m2) white- 
on-white testing (cf. devices in Table 1, Fig. 2). Moreover, red-on-white 
perimetry and red-on-cyan perimetry or blue-on-yellow perimetry may 
be applied to isolate the L/M-cone or S-cone system, respectively (Luo 
et al., 2015; Simunovic et al., 2016, 2004). These principles, as of now, 
have only been rarely applied for fundus-controlled function testing 
(Cideciyan et al., 2016; Luo et al., 2015; Remky et al., 2001; Remky and 
Elsner, 2005). 
2.4. Clinical endpoints and psychometric concepts 
2.4.1. Clinical outcome assessments 
Clinical outcome assessment (COA) qualification is a regulatory 
requirement by the U.S. Food and Drug Administration (FDA). This is 
similar with other regulatory authorities around the world including the 
European Medicines Authority (EMA). The rules state that a COA must 
be a reliable and well-defined assessment of patients’ symptoms or 
function. Hereby, FCP testing would be classified as a performance 
outcome (PerfO). Measurement properties defined by psychometric test 
theory must be considered to establish the applicability of a PerfO in 
clinical trials. This includes reliability, validity and ability to detect 
change. 
2.4.2. Reliability 
Multiple classes of reliability estimates are defined including (i.) 
intra- or inter-session test-retest reliability, (ii.) inter-method reliability, 
(iii.) inter-rater reliability and (iv.) internal consistency reliability. For 
FCP, intra-session test-retest reliability data is available for a variety of 
diseases, whereas inter-session test-retest reliability data is rare. How-
ever, for choroideremia, it has been shown that intra- and inter-session 
test-retest reliability are comparable for mesopic testing(Jolly et al., 
2017). Similarly, disease-specific data on inter-method (i.e. 
inter-device) reliability is rare. The effect of the test administrator 
(inter-examiner variability) was shown to be insignificant in the setting 
of FCP (Weingessel et al., 2009). The concepts of inter-rater reliability 
and internal consistency reliability are not applicable for FCP. 
2.4.3. Inter-device reliability 
Sensitivity measurements obtained with the same background 
should be convertible between the devices on the decibel scale through 
simple addition or subtraction of a constant (cf. 2.1.1 Wb’s law, Fechner’s 
law and the decibel scale). 
However, this could not be confirmed empirically in an inter-device 
reliability comparing the MP-1 and MAIA device (Wong et al., 2016). 
Specifically, average differences (MAIA – MP-1, mesopic testing) were 
reported ranging from 7.3 dB (Wong et al., 2016), to 5.5 dB (Steinberg 
et al., 2017), which both exceed the theoretically expected average 
difference of 4 dB (Midena, 2014). In addition to the offset, 
Bland-Altman plots revealed that the difference between the MAIA and 
MP-1 device was less pronounced for test-points with low sensitivity and 
more pronounced with high sensitivity even when excluding test-points 
close to the floor and ceiling of the dynamic range (Wong et al., 2016). 
Comparison of retinal sensitivity measurements between the MAIA and 
MP-3 device (mesopic testing) revealed a 5.65 dB difference in healthy 
observers (Balasubramanian et al., 2017), despite of the similar speci-
fications of these two devices (Supplementary Table S1). No specific 
data was reported for the inter-device reliability toward the lower end of 
the dynamic range (i.e., for patients with severe functional impairment). 
Regarding photopic FCP testing with the COMPASS device, average 
differences (Humphrey field analyzer [HFA] - COMPASS) of 1 dB for 
healthy subjects and subjects with glaucoma (Rossetti et al., 2015), and 
of 1.85 dB for healthy subjects and of 1.46 dB for subjects with glaucoma 
(Montesano et al., 2019), were previously reported. This small differ-
ence is possibly explained by the difference of the applied threshold 
strategies in the respective studies (COMPASS: ZEST or 4-2 staircase, 
HFA: SITA) (Artes et al., 2002; Montesano et al., 2019; Rossetti et al., 
2015). 
For photopic testing with the MP-3 device, average differences (HFA 
– MP-3) of 4.8 dB (patients with glaucoma) and 4.9 dB (control subjects) 
were observed (Hirooka et al., 2016). 
2.4.4. 2.4.4 Retest-reliability of FCP 
The Bland-Altman 95% coefficient of repeatability (COR or CR or 
Smallest Real Difference [SRD]) for point-wise results constitutes a 
meaningful measure of retest-reliability for FCP. The 95% COR, which is 
based on the within-subject retest-variance, describes the value below 
which the absolute differences between two measurements would lie 
with 0.95 probability (Martin Bland and Altman, 1986). Accordingly, 
point-wise changes exceeding this limit may therefore be considered as 
clinically significant (however, 5% of the test-points can be expected to 
show change beyond the 95% COR even in eyes with no change over 
time due to multiple testing). For mesopic testing using the MAIA device 
and a 4-2 staircase strategy, 95% COR of ±4.12 dB to ±4.52 dB were 
reported for diseases without deep scotomas such as intermediate 
age-related macular degeneration (Welker et al., 2018; Wu et al., 2013), 
and of ±5.79 dB to ±6.64 dB for diseases with deep scotomas such as 
geographic atrophy (Pfau et al., 2017b, 2020c; von der Emde et al., 
2019b). 
Similar point-wise 95% COR values of ±5.56 dB (with exclusion of 
floor and ceiling effects) and ±4.94 dB (without exclusion of test-points) 
were reported for the MP-1 device (Chen et al., 2009), as well as for the 
MP-3 device (±5.0 dB). However, values of 95% COR will vary with 
disease type and severity and should be investigated prior to any trials 
that aim to assess treatment effect. 
Inter-session retest-reliability has been reported less frequently, 
however, it appears to be in a similar range as intra-session retest-reli-
ability (Midena et al., 2010). 
2.4.5. Validity 
There are multiple different forms of validity. Content validity de-
scribes how well a measure matches the construct it is meant to measure. 
Content validity of FCP could be established for some devices (e.g. 
MAIA) based on the sensitivity profile matching the human photore-
ceptor distribution (Pfau et al., 2017a). Criterion validity, which in-
cludes concurrent, discriminant, convergent and predictive validity, 
describes how well a measure relates to other characteristics and mea-
sures. The most common variant to establish concurrent validity in the 
setting of FCP is structure function correlation. Further, concurrent 
validity may be established by examining the association between FCP 
results and age or best-corrected visual acuity or change over time 
(Edwards et al., 2015; Hsu et al., 2019; Jolly et al., 2017). Examples for 
discriminant validity for FCP in early and intermediate AMD is the as-
sociation of retinal sensitivity and the predominant drusen-subtype 
(Pfau et al., 2018a) and the disease stage (Cocce et al., 2018). The 
established association of the highest FCP sensitivity and full-field 
threshold (FST) in choroideremia would be an example of established 
convergent validity (Dimopoulos et al., 2018a). 
2.4.6. Ability to detect change (responsiveness, longitudinal construct 
validity) 
Knowledge of the expected disease progression in terms of sensitivity 
loss over time (dB/year) constitutes a prerequisite for sample size con-
siderations. Ability to detect change in the setting of FCP may be affected 
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by the device in presence of a ceiling effect (inability to detect mild loss 
of function) or floor effect (inability to detect worsening of severe loss of 
function) as well as by the test-pattern in conjunction with the topo-
graphic manifestation of a disease. Responsiveness of FCP in patients 
undergoing anti-vascular endothelial growth factor therapy due to 
neovascular AMD is established (Bolz et al., 2010; Prager et al., 2008; 
Squirrell et al., 2010). However, there are relatively few natural-history 
studies examining the ability to detect change in atrophic retinal disease 
(Meleth et al., 2011; Etienne M. Schönbach et al., 2020b; Testa et al., 
2014). Further, studies comparing the responsiveness of trend-based and 
event-based analysis are lacking. 
2.4.7. Clinically significant/meaningful change 
While regulatory agencies including the U.S. FDA have expressed 
explicitly a preference for functional over anatomic endpoints (Csaky 
et al., 2017), no precise criteria defining a clinically meaningful visual 
field progression have been defined for FCP in retinal disease so far. In 
contrast, the U.S. FDA previously stated in the setting of SAP and 
glaucoma, that a statistically significant between-group mean difference 
of at least 7 dB (possibly also less) may be considered as clinically sig-
nificant (Weinreb and Kaufman, 2009). For a given eye, progression of 
visual field loss may be defined by five or more visual field locations, 
which have significant changes from baseline beyond the 5% probability 
levels for the glaucoma-change-probability (GCP) analysis (De Moraes 
et al., 2017; Weinreb and Kaufman, 2009). 
3. Examination of fixation 
Fixation location and stability are recorded as a ‘byproduct’ of the 
fundus-tracking for stimulus presentations during FCP testing (Cross-
land and Rubin, 2014). The following sections will summarize previ-
ously applied types of fixation stability tests, quantitative metrics to 
describe fixation, disease-specific observations and how these mea-
surements relate to other measures of visual function. Lastly, treatment 
of fixation instability through biofeedback training will be discussed. 
3.1. Fixation testing 
Fixation examination can be conducted in two fundamental man-
ners. First, fixation characteristics may simply be recorded as part of the 
perimetry testing. Second, fixation characteristics may be acquired 
using a separate 10–30 s fixation test without perimetry testing (Cross-
land and Rubin, 2014; Longhin et al., 2013). These two types of tests 
have been previously referred to as ‘dynamic’ and ‘static’ examination of 
fixation (Etienne M. Schönbach et al., 2020a). Testing as part of the 
perimetry examination yields typically higher values for measures of 
fixation instability (Longhin et al., 2013; Etienne M. Schönbach et al., 
2020a). Another important factor, which may influence the measured 
fixation stability, is the fixation target used. Specifically, using central 
targets yields significantly smaller values for measures of fixation 
instability as opposed to pericentral fixation targets such as the “4-point 
diamond” (Bellmann et al., 2004). 
3.2. Fixation metrics 
Fixation is summarized by a measure of central tendency (i.e., locus 
of fixation) and a measure of spread (i.e., fixation stability). 
The locus of fixation, which is termed preferred retinal locus (PRL) 
for patients with extrafoveal fixation (Timberlake et al., 1987; von 
Noorden and Mackensen, 1962), is defined as the centroid of the indi-
vidual fixation point measurements. However, some patients with cen-
tral scotoma exhibit also multiple PRLs (Cummings et al., 1985; Duret 
et al., 1999; Lei and Schuchard, 1997), which may be chosen depending 
on the visual task (Crossland et al., 2011a). Crossland et al. proposed 
kernel density estimation of fixation point measurements to identify 
individual PRLs (M.D. Crossland et al., 2004). While this type of analysis 
may be performed using the raw data of the commercially available FCP 
devices, it is not integrated today. The MAIA provides two PRL locations, 
a PRLi (i for initial), which describes the centroid of fixation for the 
initial 10 s of the test prior to perimetry testing (i.e., ‘static’ examination 
of fixation), and a PRLf (f for final), which describes the centroid of all 
fixation point measurements during the exam (Morales et al., 2016). 
Differential PRLi and PRLf locations are prevalent in patients with un-
stable fixation (Morales et al., 2013). 
To quantify and report fixation stability, two types of commonly 
applied metrics coexist as well as more recent metrics, which warrant 
further investigation. First, fixation stability may be quantified in rela-
tion to fixed circular regions centered to the PRL such as a circle with a 
radius of 1◦ or 2◦ (i.e., diameter of 2◦ and 4◦, termed P1 and P2 for the 
MAIA device) (Morales et al., 2016). The so-called Fujii classification 
has been proposed, to categorize the fraction of fixation points within 
these regions as stable fixation (P1 includes greater than 75% fixation 
points), relatively unstable (P1 includes less than 75% and P2 includes 
more than 75% fixation points) and unstable (P2 includes less than 75% 
of fixations points) (Fujii et al., 2002). The early implementation of this 
classification in the MP-1 device and the simplicity contributed to a 
widespread adoption of the Fujii classification. However, it must be 
noted that this somewhat arbitrary discretization of a continuous phe-
nomenon may lead to loss of relevant information. 
A continuous measure of fixation stability is the bivariate contour 
ellipse area (BCEA) (Steinman, 1965). Typically, “global” BCEA values 
covering 63% and 95% of the fixation point measurements are provided 
(Morales et al., 2016; Steinman, 1965). Conventionally, these are log10 
transformed for subsequent statistical analyses in consideration of the 
positive skew of BCEA values (Michael D. Crossland et al., 2004). As 
mentioned above for the PRL, a subset of patients exhibits multiple PRLs. 
The spread of fixation is inadequately quantified by a single BCEA fitted 
to the fixation patient measurements in such patients. This warrants the 
proposed kernel density estimation of fixation point measurements to 
identify individual PRLs and BCEAs for these patients (M.D. Crossland 
et al., 2004). 
Importantly, a study comparing the NIDEK MP-1 device and the 
Rodenstock SLO, and a study comparing the NIDEK MP-1 and the Optos 
OCT/SLO established inter device reliability of fixation stability mea-
surements (Dunbar et al., 2010; Liu et al., 2015). For the MAIA device, 
Morales et al. provided a large reference database across a wide range of 
ages, which indicates a slight decrease of fixation stability with an in-
crease in age (Morales et al., 2016). However, pediatric subjects have 
also exhibited low fixation stability, possibly due to lower attentiveness 
(Jones et al., 2016). 
Besides the aforementioned summary metrics, new quantitative 
features have been described to describe fixation, which may be applied 
to predict visual function (e.g., visual field loss). Montesano et al. pro-
posed to incorporate the temporal relationship between points in addi-
tion to the spatial pattern of fixation point measurements (Montesano 
et al., 2018). Specifically, the sequential Euclidean distance (SED, 
average of the distances between the fixation points) was shown to be 
associated with visual field loss in eyes with glaucoma in contrast to the 
conventional BCEA(Montesano et al., 2018). However, independent 
validation data has not been reported so far. 
3.3. Fixation in retinal diseases 
While the precise selection of the PRL varies among patients with a 
central scotoma, some common trends are observable. Commonly, pa-
tients select a PRL located superiorly in the retina to the area of the 
scotoma, which results in a superior visual field defect (Crossland and 
Rubin, 2014; Fletcher and Schuchard, 1997). This is theoretically ad-
vantageous for reading as well as spotting inferior obstacles such as steps 
(Crossland and Rubin, 2014; Sunness et al., 1996). However, these 
theoretical advantages often do not translate in improved reading speed 
(Crossland et al., 2005). Moreover, the specific disease also affects 
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selection of the PRL. Patients with Leber hereditary optic neuropathy 
(LHON) were shown to self-select frequently unfavorable PRL locations 
(Altpeter et al., 2013). Patients with a central scotoma secondary to 
Stargardt disease were shown to more consistently select a PRL superior 
to the scotoma than patients with GA secondary to AMD (Sunness et al., 
1996). Interestingly, patients with Stargardt disease tend to select a PRL 
not at the margin, but at some distance away from the boundary of 
RPE-atrophy (Sunness et al., 1996). A possible explanation may be that 
scotomas boundaries were shown to exceed areas of RPE-atrophy in 
some patients with Stargardt disease (Sunness, 2008). In eyes with 
diabetic macular edema, the fixation location was previously shown to 
be independent of the edema characteristics, but strongly associated 
with the presence of subfoveal hard exudates (Vujosevic et al., 2008).In 
terms of fixation stability, macular diseases such as AMD and Stargardt 
diseases exhibit the worst fixation stability, whereas patients with reti-
nitis pigmentosa are more likely to present with stable fixation, as ex-
pected due to relative central preservation until late in the disease 
(Amore et al., 2013; Crossland and Rubin, 2014; Fujii et al., 2002). 
Patients with glaucoma and diabetic maculopathy exhibit a wide range 
of fixation stabilities, dependent on disease severity (Dunbar et al., 
2010; Montesano et al., 2018). Overall, fixation stability correlates well 
with other measurements of visual function such as reading speed and 
BCVA, which underscores the concurrent validity of fixation stability 
metrics (Amore et al., 2013; Michael D. Crossland et al., 2004). 
The precise determinants for PRL selection in a given patient are only 
partially understood. It has been shown that fixation stability improves 
markedly over the first year after losing central vision (Michael D. 
Crossland et al., 2004). These changes explain 52% of the variability in 
concurrent improvement of reading speed (Michael D. Crossland et al., 
2004). Nevertheless, some data suggests that the natural choice of PRL 
in patients may not necessarily constitute the optimal PRL (Denniss 
et al., 2017; Timberlake et al., 1987). Specifically, an early hallmark 
study by Timberlake et al. using the SLO images of pathology showed 
that asking patients to use a different PRL may improve reading speed 
(Timberlake et al., 1987). Similarly, Denniss et al. demonstrated in a 
large cohort of patients with AMD, that the self-selected PRL tends to be 
located just foveal to a region of relatively normal sensitivity, suggesting 
that slightly more eccentric fixation may improve vision (Denniss et al., 
2017). In conjunction, such findings suggest that the PRL position may 
be amenable to fixation training. 
3.4. Eccentric viewing and fixation stability training 
Despite of a large number of publications on eccentric viewing 
training in general, only few randomized trials are available (Gaffney 
et al., 2014). To the best of our knowledge, no randomized trial on 
eccentric viewing training employing a commercially available FCP 
device has been published to date. 
Smaller, single-arm studies suggest that auditory biofeedback 
training aiming to optimize the PRL position and fixation stability may 
potentially improve fixation stability as well as visual acuity and reading 
speed (Morales et al., 2015; Tita-Nistor et al., 2009; Vingolo et al., 2009, 
2007). This type of training is possible with the MP-1, MP-3 and MAIA 
device. Alternatively, visual biofeedback training may be performed 
with the MP-1 and MP-3 device with a checkboard pattern, which 
flickers upon fixation with the desired PRL (Vingolo et al., 2013). Mo-
rales et al. recently evidenced in a two-arm study that biofeedback 
training results in superior fixation stability when using an 
examiner-selected PRL (based on retinal sensitivity) as opposed to fix-
ation stability training for the self-selected PRL (Morales et al., 2020). 
Although the PRL may be amenable to training, the question of 
which location to choose for training is non-trivial. A common concept is 
to identify a location superior to the scotoma in retinal space (to provide 
a free inferior visual field for unhindered reading), that exhibits retinal 
sensitivity better than at the self-selected PRL and in proximity to the 
fovea (in consideration of spatial resolution) (Tita-Nistor et al., 2009). 
However, the relationship between sensitivity measured by FCP devices 
and acuity for non-foveal locations in patients with AMD is not strong, 
even if eccentricity is taken into account (Denniss et al., 2018). This 
suggests that FCP-measured sensitivity may not be a good basis for PRL 
selection. It may be advantageous to select a PRL based on a more 
complex combination of factors prior to training with an FCP device, 
though this remains to be tested. 
4. Previous application in clinical studies and trials 
Please note: If not stated explicitly otherwise, numerical values in 
the following paragraphs refer to mesopic testing with the MAIA device 
and a 4–2 threshold strategy in view of the overall data availability. 
4.1. Early and intermediate age-related macular degeneration 
The disease progression from normal aging to early or intermediate 
AMD is slow and typically not associated with a loss of best-corrected 
visual acuity (Lim et al., 2012). Intra-session retest-reliability was re-
ported with 95% COR estimates ranging from ±4.12 dB to ±4.4 dB 
(Welker et al., 2018; Wu et al., 2013). Mesopic retinal sensitivity 
measured by FCP deteriorates with worsening disease severity from 
normal to early and then intermediate AMD, correlates with SD-OCT 
retinal layer thicknesses, drusen thickness and presence of hyper-
reflective foci as well as integrity of the ellipsoid zone (Cocce et al., 
2018; Echols et al., 2020; Hartmann et al., 2011; Wu et al., 2016a, 
2015a, 2014). These findings demonstrate the utility of FCP as a marker 
of early disease progression. However, macular sensitivity did not 
exhibit significant association with quality of life assessed by the Impact 
of vision Impairment questionnaire (IReST) (Pondorfer et al., 2019). 
Regarding ability to detect change, rather wide-ranging estimates for the 
rate of change for mesopic sensitivity have been reported, ranging from 
− 0.48 dB/year in the LEAD study (sham group) to up to − 3.0 dB/year in 
smaller longitudinal studies (Hsu et al., 2019; Wu et al., 2019c). A 
long-term study over 6 year in 16 patients reported a mean reduction of 
sensitivity by 0.61 dB/year for early and by − 1.8 dB/year for interme-
diate AMD, respectively (Vujosevic et al., 2017a). The recently 
completed 2 year Duke University natural history study on early AMD 
(Cocce et al., 2018) and the recently initiated EU-funded MACUSTAR 
study, the ALSTAR2 study, and the NEI-initiated AMD Ryan Initiative 
Study (ARIS) aim, among validation of other functional and imaging 
tests, to further asses the rate of sensitivity change in patients and to 
identify prognostic markers (Curcio et al., 2020; Finger et al., 2019). In 
prior publications, comparison of mesopic and dark-adapted thresholds 
revealed systematically greater degrees of rod-dysfunction compared to 
cone-dysfunction, especially in presence of reticular pseudodrusen and 
thinning of the outer nuclear layer (Corvi et al., 2019; Pfau et al., 2018a; 
Saβmannshausen et al., 2018; Steinberg et al., 2016, 2015). Similar re-
sults were observed in the Amish Eye Study using the MP-1 device 
(Nittala et al., 2019). 
4.2. Choroidal neovascularization secondary to AMD 
Clinical trials investigating choroidal neovascularization (CNV) 
secondary to AMD have been limited to patients with foveal involve-
ment due to the dependence on BCVA as an outcome measure. FCP 
provides the opportunity to evaluate patients with extrafoveal and peri- 
papillary lesions and may be useful to identify treatment benefits 
beyond of the marked effect of anti-VEGF therapy (von der Emde et al., 
2019b). Intra-session retest-reliability estimates (COR of ±5.99 dB), as 
well as data supporting discriminant validity among eyes with 
non-exudative (quiescent), exudative (active) and formerly exudative 
(inactive) lesion is available (von der Emde et al., 2019b). Moreover, 
structure function correlation using an artificial intelligence algorithm 
(von der Emde et al., 2019a), as well as conventional structure function 
correlation (Sulzbacher et al., 2012), demonstrated concurrent validity. 
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Ability to detect change in terms of mesopic sensitivity was established 
in longitudinal studies examining the effect of photodynamic therapy 
(Schmidt-Erfurth and Michels, 2003), and anti-VEGF therapy (Bolz 
et al., 2010; Prager et al., 2008; Squirrell et al., 2010). Greater degrees of 
dark-adapted versus mesopic sensitivity losses were reported for pa-
tients with CNV secondary to AMD (von der Emde et al., 2019b). 
4.3. Geographic atrophy secondary to AMD 
BCVA acuity is unsuitable as a functional outcome measure in patient 
with geographic atrophy (GA) until the end-stage of manifestation of 
atrophy (Csaky et al., 2019). A frequent feature of GA is initial foveal 
sparing. Foci of GA typically manifest outside of the fovea representing 
absolute scotomas (Lindner et al., 2017; Sunness et al., 2008). Specif-
ically, the Age-Related Eye Disease Study 2 (AREDS2) Ancillary SDOCT 
study demonstrated, that 26.4% of patients develop any GA (central or 
non-central) over a follow-up of 4 years, while only 15.8% develop 
central GA (Sleiman et al., 2017). Hence, multiple investigators have 
evaluated fundus-controlled perimetry as an alternative to BCVA (Hariri 
et al., 2016; Meleth et al., 2011; Pfau et al., 2020c; Phthalmology, 2016; 
Pilotto et al., 2013; Schmitz-Valckenberg et al., 2004; Scholl et al., 2004; 
Sunness et al., 1995; Takahashi et al., 2016). Estimates for the 
retest-reliability (COR ±6.64 dB) have been reported (Pfau et al., 
2020c), as well as structure function analyses demonstrating that mes-
opic sensitivity is especially reduced in the immediate junctional-zone of 
375 μm (Pfau et al., 2020c; Schmitz-Valckenberg et al., 2004), and in 
association with increased autofluorescence (Pilotto et al., 2013; 
Schmitz-Valckenberg et al., 2004), loss of the outer nuclear layer and/or 
photoreceptor inner and outer segments (Hartmann et al., 2011; Landa 
et al., 2011; Pilotto et al., 2013; Takahashi et al., 2016). Ability to detect 
change could be established in a longitudinal study with a rate of − 1.05 
dB/year for the MP-1 device using a 10–2 test pattern (Meleth et al., 
2011). Fundus-controlled perimetry served as secondary outcome 
measure in the large-scale, phase-3 studies for Lampalizumab (Holz 
et al., 2018) and reported (MP-1, 10-2 pattern) an average decline of the 
mean sensitivity of 1.27 dB (sham group) in 48 weeks (Heier et al., 
2020). So-called patient-tailored perimetry patterns allow for an 
increased density of test-points in the junctional-zone and thus improve 
the ability to detect change (cf. 5.2 Test patterns) (Pfau et al., 2020c). 
Dark-adapted sensitivity losses were shown to be greater in proximity to 
GA compared to mesopic sensitivity losses (Pfau et al., 2020c). A recent 
important observation has been that (minimal) residual cone- but not 
rod-function is detectable in areas with loss of retinal pigment epithe-
lium with persistent overlying outer nuclear layer (Pfau et al., 2019). Of 
note, the retinal sensitivity was only minimal and no rod function could 
be detected. 
4.4. Diabetic retinopathy 
While foveal-involving diabetic macular edema may be monitored 
with BCVA, FCP facilitates the quantification of functional loss due to 
extrafoveal macular edema or generalized ischemic diabetic maculop-
athy (Comyn et al., 2014; Querques et al., 2014; Rohrschneider et al., 
2000). A plethora of structure function analysis studies have under-
scored the validity of FCP as an important determinant of various types 
of pathological processes, including macular edema/retinal thickening 
(Deák et al., 2010; Vujosevic et al., 2017b, 2006), photoreceptor inner 
and outer segment integrity (Yohannan et al., 2013), hyperreflective 
spots (Vujosevic et al., 2016), autofluorescence characteristics (Vujo-
sevic et al., 2011), as well as retinal perfusion based on optical coher-
ence tomography angiography (Alonso-Plasencia et al., 2019; Tsai et al., 
2019). In type 1 diabetes, electrophysiological changes can be observed 
prior to fundoscopic signs. Early abnormalities in retinal sensitivity were 
not observed, However, the study used the MP-1 device, which is un-
suitable to quantify early functional loss (cf. 2.1.8 Dynamic range, ceiling 
and floor effects) (Sacconi et al., 2019). 
4.5. Central serous chorioretinopathy 
In central serous chorioretinopathy (CSCR), concurrent validity 
could be established based on structure function correlation (Eandi 
et al., 2015; Fujita et al., 2012; Gerendas et al., 2018; Springer et al., 
2006) as well as correlation with sub-scales of the National Eye Institute 
25-Item Visual Function Questionnaire (Gerendas et al., 2018). Inter-
estingly, a small study even provided evidence for predictive validity of 
FCP in CSCR with regard to the future persistence of subretinal fluid 
(Roisman et al., 2014). Ability to detect change was demonstrated in the 
prospective, randomized PLACE trial (van Dijk et al., 2018). 
4.6. Macular telangiectasia (MacTel) type 2 
Macular telangiectasia (MacTel) type 2 is a relatively rare disease 
that manifests initially in the temporal parafoveal region, but with 
progression can spread to affect an oval macular region that is wider 
along the horizontal meridian. A large multicenter study using the MP-1 
device could quantitatively demonstrate that functional loss is indeed 
limited to this oval “MacTel area” (approx. 8◦ horizontally and 4◦
vertically) regardless of the disease severity (Vujosevic et al., 2018). 
Given the characteristic spatial localization of this condition, previously 
used test patterns have often had a higher sampling density in this 
central oval region. FCP testing is overall well characterized in terms of 
reliability, validity and ability to detect change (Charbel Issa et al., 
2013, 2007; Schmitz-Valckenberg et al., 2009, 2008). A intra-session 
retest-reliability of (COR) ±7.2 dB has been reported for the central 
test-point (Wong et al., 2017). Concurrent validity was established based 
on the tight structure function correlation with areas of loss of the EZ 
(Heeren et al., 2017; Kihara et al., 2019; Mukherjee et al., 2017) as well 
as the association to reading acuity (Tzaridis et al., 2019). Moreover, 
FCP was shown to be more responsive to change over time than BCVA 
(Heeren et al., 2015). Mesopic FCP was applied as secondary outcome 
measure in the Ciliary Neurotrophic Factor (CNTF) implant trial (Chew 
et al., 2019). Rod dysfunction exceeds cone dysfunction in the parafo-
veal areas, typically affected by MacTel (Schmitz-Valckenberg et al., 
2009, 2008). Further, in patients with macular pigment optical density 
(MPOD) class 1 patients, dark-adapted cyan sensitivity losses were 
shown to exceed dark-adapted red sensitivity losses (Heeren et al., 
2019). 
4.7. Stargardt disease 
Stargardt disease (ABCA4-associated retinal degenerations), one of 
the most common inherited retinal diseases, exhibits a central-to- 
peripheral disease progression, commonly in conjunction with foveal 
and peri-papillary sparing (Cideciyan et al., 2009, 2005; Müller et al., 
2018). Accordingly, BCVA is inadequate to capture functional loss over 
time. The ProgStar studies represent the largest collection of retro-
spective and prospective assessment of the natural history of Stargardt 
disease. In addition, a number of other groups have assessed patients 
with Stargardt using FCP. Concurrent validity could be established in the 
context of the ProgStar study demonstrating a correlation of mesopic 
sensitivity with BCVA as well as patient age and disease duration 
(Schönbach et al., 2017). Ability to detect change was also documented 
by the ProgStar study (MP-1 device, 10-2 grid) with a rate of change of 
− 0.68 dB per year (Ervin et al., 2019; Etienne M Schönbach et al., 2020). 
In the ancillary ProgStar study SMART (Scotopic Microperimetric 
Assessment of Rod Function in Stargardt Disease) using the MP-1-S de-
vice, a higher rate of scotopic (− 1.42 dB/year) versus mesopic sensi-
tivity (− 0.63 dB/year) loss over time compared was observed (Ervin 
et al., 2019). Recently, it has been shown that analysis of the subset of 
test-points at the scotoma edge improves the ability to detect change 
over time (Etienne M. Schönbach et al., 2020b). 
As an alternative to rectilinear test-patterns, Cideciyan and co-
workers proposed the application of the horizontal foveo-papillary 
M. Pfau et al.                                                                                                                                                                                                                                    
Progress in Retinal and Eye Research 82 (2021) 100907
11
profile as test-pattern. Since this profile encompasses the fovea, as well 
as peripapillary region, it is typically highly representative of the overall 
disease severity in most patients with Stargardt disease (Cideciyan et al., 
2012). Ability to detect change (as well as retest-variability estimates 
and concurrent validity) have been later established for the horizontal 
profile in patients with Stargardt disease as part of a longitudinal study 
(Pfau et al., 2020b). FCP has served as outcome measure in previous 
clinical studies for Stargardt disease investigating cellular replacement 
therapies (Mehat et al., 2018), and constitutes a functional outcome 
measure in multiple ongoing trials (e.g., NCT03992131). 
4.8. Retinitis pigmentosa 
Retinitis pigmentosa, a heterogeneous group of Mendelian disorders 
characterized by a progressive peripheral-to-central retinal degenera-
tion, necessitates the quantification of the visual field to evaluate vision 
loss over time. Concurrent validity has been established based on 
structure function correlation. Specifically, it was shown that the sco-
toma boundary detected by FCP matches closely the circular boundary 
of abnormal autofluorescence (‘Robson-Holder ring’) (Fleckenstein 
et al., 2009; Robson et al., 2003), as well as the boundary of the 
photoreceptor inner and outer segments visualized by OCT (Greenstein 
et al., 2012; Wakabayashi et al., 2010). Moreover, retinal sensitivity was 
shown to correlate closely with the outer retinal thickness (Funatsu 
et al., 2019). Intra- and inter-session retest data is available for the 
common X-linked retinitis pigmentosa subtype (RPGR gene) with a re-
ported point-wise COR estimate of ±6 dB (Buckley et al., 2020). Ability 
to detect change could be established in the context of the PREP-1 Study 
(rate of − 0.4 dB/year, MP-1 device, 10-2 grid) (Iftikhar et al., 2018). 
Moreover, dedicated analysis of test-points at the edge of scotoma has 
been proposed in the context of USH2A retinopathy to optimize the 
ability to detect change (Charng et al., 2020a). 
Ongoing gene therapy trials for retinitis pigmentosa caused by mu-
tations in RPGR are utilizing FCP as outcome measure (e.g. 
NCT03116113).(Buckley et al., 2020; Cehajic-Kapetanovic et al., 2020). 
4.9. Choroideremia 
Choroideremia (CHM), a rare, inherited, X-linked recessive retinal 
disease, presents with night blindness and progressive visual field re-
striction in late childhood and leads typically to severe vision loss in the 
fourth decade. The retest-reliability has been evaluated for the MAIA 
device (COR of ±8.7 dB) (Dimopoulos et al., 2016; Jolly et al., 2017). 
Concurrent validity of FCP has been well established given the close 
correspondence of the scotomas boundary and the boundary of the re-
sidual functional retina as visualized by fundus autofluorescence 
(Dimopoulos et al., 2016; Jolly et al., 2017), or OCT imaging (Foote 
et al., 2019). Further, a weak correlation between mean central sensi-
tivity and reading speed has been reported (Jolly et al., 2019). Ability to 
detect change has been estimated with cross-sectional data for mesopic 
testing with a 10-2 grid based on an exponential model (Jolly et al., 
2017). The absence of the necessity for pupil dilatation and dark 
adaptation prior to mesopic testing with the MAIA device has also been 
studied and confirmed for this patient group (Han et al., 2019, 2017). 
Further, correlation of FCP sensitivity to rod- and cone-full-field 
thresholds (FST) in choroideremia supports convergent validity 
(Dimopoulos et al., 2018a). Recently, evidence of functional cones in 
conjunction with residual outer nuclear layer outside the boundary of 
RPE-atrophy has been brought forward (Foote et al., 2019). FCP has also 
been applied to quantify retinal dysfunction in choroideremia carriers 
(Edwards et al., 2015). In this cohort, mesopic sensitivity was shown to 
correlate with the degree of loss of RPE autofluorescence (Edwards et al., 
2015). Mesopic FCP served as secondary outcome in multiple gene 
augmentation therapy trials for CHM (Dimopoulos et al., 2018b; Fischer 
et al., 2020; MacLaren et al., 2014; Simunovic et al., 2017). 
4.10. Glaucoma 
Glaucoma, a progressive optic neuropathy with characteristic 
morphological changes of the optic disc, ranks among the most common 
causes of irreversible vision loss worldwide. Visual field testing consti-
tutes the key functional outcome measure in glaucoma, given that other 
types of visual function such as BCVA are spared initially (Weinreb et al., 
2014). While SAP is the gold standard for visual field testing in glau-
coma, SAP may miss early visual field defects (‘pre-perimetric glau-
coma’) and detection of disease progression in advanced disease may be 
impeded due to relatively high test-retest variability. Specific subtypes 
of glaucoma causing localized defects in the central retina can be 
effectively assessed with FCP (Ratnarajan et al., 2018; Yusuf et al., 
2018). Dense circular peripapillary patterns have been explored for 
early detection of glaucoma with FCP (cf. 5.2 design of perimetry 
test-patterns), since these may be advantageous to detect fine nerve fiber 
bundle defects (Convento et al., 2006; Rohrschneider et al., 1996; Wu 
et al., 2016b). However, this advantage may be outweighed by the 
presence of high local gradients of sensitivity (such as those associated 
with localized defects) that often have a higher degree of measurement 
variability (Wu et al., 2016b). Regarding detection of diseases progres-
sion, the precise source of the high test-retest variability of SAP in 
glaucoma has been attributed to response characteristics of the retinal 
ganglion cells and/or incorrect stimulus placement in irregular visual 
fields (Wall et al., 2010; Wu et al., 2019a; Wyatt et al., 2007). The latter 
source of test-retest variability may be ameliorated by fundus-tracking 
(Wu et al., 2016b). In comparison to SAP with the Humphrey Field 
Analyzer, FCP with the COMPASS device was shown to exhibit better 
test-retest reliability (Montesano et al., 2019; Rossetti et al., 2015). To 
our knowledge, data regarding ability to detect disease progression is 
not yet available. 
4.11. Other macular diseases 
Application of FCP has been applied in multiple other retinal diseases 
beyond the scope of this article. This includes (among other) disease, 
retinal vein occlusion (Fujino et al., 2020; Kriechbaum et al., 2009; 
Sachdev et al., 2019), as well as toxic retinopathies and inflammatory 
diseases (Fang et al., 2017; Martínez-Costa et al., 2013; Szepessy et al., 
2019; Youssef et al., 2017). 
5. Best practices and clinical trial design 
5.1. Best practices 
The accuracy and reliability of FCP is significantly affected by test 
procedure and processes, with several factors having an impact on the 
outcome. Although, FCP is considered an automated procedure, the 
operator has significant control over the outcome of the test. This section 
will go through these factors and discuss further with the aim of 
providing practical advice to optimize data collection. 
5.1.1. Adaptation state of the retina and the patient 
Early FCP studies employed a variety of adaptation times before 
conducting the test in order to account for a mixed rod-cone response 
and allow for adequate rod adaptation. However, several recent studies 
have shown that standard mesopic FCP is largely a measure of cone 
function (Crossland et al., 2012; Han et al., 2019; Simunovic et al., 
2016) and therefore adaptation before conducting FCP is not required if 
the patient has only had exposure to ambient lighting. This has been 
specifically demonstrated in the setting of choroideremia (Han et al., 
2019). Patients with rod-cone dystrophies subjectively report higher 
comfort when tested after some level of dark adaptation, therefore 2–5 
min may be offered to aid patient compliance (Han et al., 2019). We also 
recommend that room lighting is switched off and background lumi-
nance is restricted (<1 lux) to ensure that the test luminance parameters 
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are not altered artificially but examiner movement around the room is 
still facilitated. Later models of the MAIA are outfitted with a red filter to 
fit over the screen, whose role is to block short-wavelength light from 
bleaching rod photoreceptors. Similarly, the MP-3 Type S screen may be 
operated in low-light, red-shifted mode to preserve a scotopic 
environment. 
Generally, FCP testing should be performed prior to imaging. How-
ever, if the test is preceded by bright light exposure such as photography 
or a slit lamp examination, then 10 min of dark adaptation is recom-
mended to allow bleached cones to recover and ensure all patients are at 
the same level of retinal adaptation before testing (Han et al., 2019). 
Scotopic FCP is a relatively new procedure and has limited investi-
gation into best procedures to be followed. As guidance, we recommend 
dark adaptation of at least 20 min for normal subjects and patients with 
retinal diseases not affecting the rate of rhodopsin regeneration (Lamb 
and Pugh, 2004), whereas longer periods of dark adaptation are war-
ranted for diseases that affect Bruch’s membrane interchange such as 
AMD, or proteins of the visual cycle (Lamb and Pugh, 2004). For AMD 
patients, 30 or 40 min of dark adaptation have been previously used in 
FCP studies in consideration the burden for elderly patients (Pfau et al., 
2020c; Steinberg et al., 2015). However, longer dark adaptation may be 
preferable to ensure complete dark adaptation for all patients (Chen 
et al., 2019; Luu et al., 2018; Owsley et al., 2007). 
5.1.2. Pupil dilation 
The technical specifications for the MAIA and MP-3 microperimetery 
devices specify a minimum pupil diameter of 2.5 mm and 4 mm 
respectively. Under the mesopic conditions most patients do not need to 
be dilated to meet these requirements (cf. 2.5.2 Maxwellian view versus 
natural viewing optical systems). Unlike with traditional perimetry, pupil 
dilation does not seem to degrade FCP performance (Han et al., 2017). 
However, we do recommend that in a clinical trial setting all subjects 
should be tested in the same manner, i.e. all participants should be 
dilated or all un-dilated during all visits. 
5.1.3. Set up, instruction, and practice examinations 
Lubricating eye drops (artificial tears) should be offered to all pa-
tients with an unstable tear film. To ensure a comfortable position for 
the patient, the perimeter should be on a height adjustable table and set 
to a comfortable height. Generally, the distance between the chair and 
forehead rest should be set-up to result in minimal forward pressure 
against the forehead rest, which tends to be easier to hold than a neutral 
position. Patient stability and comfort will increase compliance as head 
movement is less likely. 
Careful instruction should be provided on the purpose of the exam-
ination and the process involved (Glen et al., 2014). Instruct the 
participant to look at the fixation target or towards the center of the 
target if a circle is used. Most machines incorporate an additional large 
fixation area for patients with poor central visual acuity. However, these 
will alter the fixation stability recording (Bellmann et al., 2004). Newer 
models also allow the use of a peripheral fixation target. The author has 
also used the SLO image to verbally guide fixation in patients with low 
vision with great success. Although some devices provide auditory 
feedback when the eyes move out of alignment, the observer should 
monitor and optimize alignment throughout the examination. 
During the set-up period, the SLO/fundus image should be centered 
and fill the screen. The auto-alignment function often requires addi-
tional adjustment. The focus can be set by moving the eyepiece forward 
and backwards. The auto-focus function often requires additional 
manual input. In other imaging modalities, the importance of optimal 
focus has been established (Issa et al., 2012). The same applies in FCP as 
the focus sets the plane in which sensitivity is tested so cannot be 
changed once started. The accuracy of the focusing also will dictate the 
accuracy of the sensitivity measurement (Fig. 3). For follow-up exami-
nations the focus should match the initial examination as much as 
possible to ensure the tests are comparable and reduce variability. In the 
authors experience, reliability can also be reduced by the patient 
becoming over stressed or over accommodating. This manifests as an 
intermittently blurred image with no apparent movement. 
Further, the automatic grid placement for the initial examination, as 
implemented in all devices, will center the grid on the PRL of the first 10 
s. Accordingly, the operator should emphasize correct fixation during 
this time window. For patients with unstable fixation, the manual grid 
placement options of the device must be used. 
Unlike for BCVA testing (Bach and Schäfer, 2016), the effect of 
auditory feedback originating from the machine has not been studied 
systematically for FCP. However, previous work on training in perimetry 
showed that patients valued continuous instruction and feedback (Glen 
et al., 2014). Moreover, Allison M. McKendrick and coworkers recently 
demonstrated in the setting of SAP that auditory feedback by a human 
operator (or a humanoid robot) enhances the subjective experience of 
perimetry test, while not altering the test results (McKendrick et al., 
2019). Accordingly, the patient should be frequently reassured and 
encouraged with updates provided on test progress. This encourages 
co-operation and keeps the patient alert. 
Perimetry is a difficult test and requires training to perform accu-
rately. In both healthy eyes and disease, practice examinations are 
required in order to avoid biased results due to a learning effect (Rat-
narajan et al., 2018; Wu et al., 2013). Likewise, the European Glaucoma 
Society guidelines recommend in the setting of SAP a re-test for patients 
with borderline test results for their first test, as well as three tests per 
year during the first two years after diagnosis to document progression 
(European Glaucoma Society, 2017). Thus, we recommend for clinical 
trials using FCP that the first test to be discarded to increase accuracy of 
the results. 
Fatigue will reduce the reliability of the testing so should be 
accounted for when setting the study protocol. Visual field testing is an 
intense test requiring significant patient concentration. In the authors 
center, we prioritize FCP testing to be conducted early in the test day or 
following a break in the day to ensure the patient is as refreshed as 
possible. Breaks can be offered during testing but it can be difficult to 
realign the patient accurately, particularly if they have low vision and 
reduced ability to see the fixation target. Fatigue is more likely to occur 
in the presence of disease and with a longer test time (Johnson et al., 
1988; Wildberger and Robert, 1988). Patients with moderate visual field 
loss associated with depressed sensitivities across the visual field have 
longer test times which is a factor to consider when planning for fatigue 
effects. 
5.1.4. Test choice 
A number of test options are available as standard. Custom tests can 
easily be created and uploaded into most fundus controlled perimetry 
devices. The choice of test will be determined by the research or clinical 
question. The most common test configurations appearing in the liter-
ature on assessments of mesopic FCP are the rectilinear 10-2 grid and 
radial patterns (cf. 5.2 Design of perimetry test-patterns). 
For follow up exams, the follow up mode should be used to ensure 
stimulus presentation the identical location (even for patients with un-
stable fixation). 
5.1.5. Early termination of a test 
To minimize patient burden, it is sometimes helpful to terminate a 
test prematurely and repeat the test. Common reasons are displacement 
of the test pattern or obvious errors of the threshold determination of the 
first four test-points. For some devices, the first four thresholds define 
the initial intensity for the staircase procedure for the remaining test- 
points in the given quadrant. Accordingly, false-positive responses 
among the first four test-points may result in excessively long exam 
durations. 
Moreover, an incorrect initial intensity determination for a given 
quadrant may result in erroneous threshold determinations at neigh-
boring test points, since it would take many more “correct” responses at 
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these locations to converge to the true threshold. For example, if a region 
is truly scotomatous and the initial presentation starts at 24 dB, six true- 
negative responses are required to reach a final value of <0 dB. Thus, the 
likelihood of a false-positive response affecting the results in regions 
with a deep scotoma are higher compared to regions with normal 
sensitivity. 
5.1.6. Operator training 
During testing, there is a lot of information on the operator screen 
that should be monitored to ensure high quality data is collected. The 
camera image will provide information on the eye position and move-
ment with an auditory cue when the eye position falls outside of toler-
ance. The cause of this change in position must be determined. In some 
cases, it may be head tilt or movement resulting in non-contact with the 
forehead rest, a change in accommodative effort of the eye, poor posi-
tioning at the machine making it difficult to keep the head still, or, true 
movement in the X, Y or Z axes. Each of these present in a subtly 
different way and involve differential instructions to the patient to 
remedy. The individual points being tested are shown in real time and 
when the response button is pressed and registered, this information is 
also shown on the screen. Further, false-positive responses to catch-trials 
at the optic nerve head must be recognized by the operator in order to 
provide adequate ongoing instruction. Test progression in terms of 
points with convergence of the staircase (i.e., determined threshold) is 
reported as a percentage, allowing positive encouragement about 
progress to be reported to the patient. 
This is a lot of information that must be monitored in real time by the 
operator to ensure test reliability and patient comfort. Previous work on 
complex screens has shown change blindness to occur with operators 
missing key information (Durlach, 2004). This establishes the impor-
tance of adequate training to conduct FCP. Key strategies to improve 
performance include attention to the relevant details, being able to 
discern when a relevant change has occurred such as a blindspot 
catch-trial, order of features being attended, experience, training on the 
specific interface, markers alerting problems, and the minimization of 
distractions and interruptions (Durlach, 2004). Some features are going 
to vary between patients. For example, some patients will alter their 
fixation more often so eye movement will require greater attention than 
other factors. Other patients are more likely to become fatigued or 
impatient and require frequent updates on progress. Greater experience 
of conducting FCP allows the operator to learn the factors that require 
greater attention and hone in on these. Working in a quiet room free of 
distractions is helpful to both the operator and the patient. There are 
several alert markers presented, both visual and auditory. However, 
some of the visual cues such as the color change around the frame of the 
fundus image can be quite difficult to see through the red filter and may 
require greater attention when these are variable and require more 
robust monitoring. 
5.1.7. Key points 
The accuracy of FCP testing can be improved by following a few key 
procedural points:  
1) Adequate training of the operator and adequate instruction as well as 
practice for the patient.  
2) Proper test set up and image focusing.  
3) Ten minutes adaptation to ambient lighting following intense light 
exposure.  
4) Consistency in dilation state between visits in a clinical trial setting.  
5) Careful consideration of the testing order.  
6) Ensure correct grid placement  
7) Careful monitoring of the reliability factors and adequate continuous 
instruction to correct any errors. 
5.2. Design of perimetry test-patterns 
In principle, two overarching categories of test patterns are 
conceivable: Fixed and patient-tailored patterns. Hereby, the test-points 
of fixed patterns are located across all patients at the same position in 
relation to ocular landmarks (fovea and optic disc). This may be ach-
ieved by testing of patients with foveal fixation or through manual 
positioning of the test pattern. Fixed patterns simplify analysis mark-
edly, since mean sensitivity loss and pattern deviation may be easily 
calculated with normal data obtained with the same respective pattern 
(Fig. 4). 
Displaced “fixed patterns” (i.e., application of a fixed pattern in a 
patient with eccentric fixation and without re-positioning of the test 
pattern) may be considered as a special case of a patient-tailored 
pattern. For such displaced test-patterns, analysis strategies employing 
spatially interpolated normative data are also necessary (cf. 5.2.1 
Patient-tailored test-patterns). 
5.2.1. Fixed test-patterns 
Fixed test patterns can be further subdivided in (1.) rectilinear grids, 
(2.) radial grids and (3.) profiles, which are typically centered to the 
fovea, and (4.) circular peripapillary patterns: 
1. The most commonly applied rectilinear grid in FCP is the 10-2 
grid. Due to the uniform spacing of stimuli, indices such as the mean 
sensitivity or mean deviation are reflective of the underlying visual field 
and therefore easy to interpret (Pfau et al., 2018b). Generally, the 10-2 
grid should constitute the preferred choice in acquired and inherited 
retinal diseases that affect the entire macula (Fig. 4) (Jolly et al., 2017). 
However, the test duration using a 10-2 grid is often long with the 
currently available staircase strategies. 
2. In contrast, radial patterns (Fig. 4), which are also commonly 
applied in FCP, will result in spatially-weighted averages. This weight-
ing increases the influence of foveal and parafoveal regions with higher 
sampling density in the indices. Accordingly, comparison among results 
generated with various radial patterns is challenging. It may however be 
advantageous for the establishment of concurrent validity, since the 
majority of visual function tests are more strongly associated with 
central retinal function compared to peripheral function (e.g., BCVA). Of 
note, topographic modeling may be applied to derive spatially- 
unweighted visual indices even for data acquired using radial test- 
patterns (Josan et al., 2020; Weleber et al., 2015). 
3. Profiles along the horizontal or vertical meridian (Fig. 4) consti-
tute the third category of fixed patterns. Especially in inherited retinal 
diseases with a somewhat uniform centrifugal or centripetal progression 
such as retinitis pigmentosa, disease progression is reflected well by the 
function along the horizontal meridian. Moreover, relevant regions in 
Stargardt disease including the degree of foveal and peripapillary 
sparing may be investigated along the horizontal meridian (Cideciyan 
et al., 2012). 
4. Circular peripapillary patterns (Fig. 4) may be applied in the 
context of glaucoma and other diseases of the optic nerve head to detect 
peripapillary nerve fiber bundle defects (Convento et al., 2006; 
Rohrschneider et al., 1996; Wu et al., 2016b). Dense sampling of the 
peripapillary region using FCP may allow detection of functional losses 
missed with the coarse rectilinear patterns for glaucoma (Convento 
et al., 2006; Rohrschneider et al., 1996), and may be easily correlated to 
the common circular SD-OCT retinal nerve fiber layer thickness scans 
(Wu et al., 2016b). 
A special case of rectilinear patterns are composite rectilinear pat-
terns as previously applied in Macular Telangiectasia Type 2 (Charbel 
Issa et al., 2007). A denser test-point spacing for the central macula (2◦
spacing) compared outer macula (4◦ spacing) was applied in consider-
ation of the disease topography (Charbel Issa et al., 2007). Similar to 
radial patterns, the mean sensitivity of such a pattern must be consid-
ered as spatially-weighted mean. 
A second special case is the use of a rectilinear grid with a very high 
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Fig. 4. Fixed perimetry patterns.  
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density in combination with a very coarse staircase strategy or no 
staircase strategy (i.e., fixed intensity suprathreshold testing). This 
approach, which provides high spatial resolution, but low resolution in 
terms of sensitivity, has been proposed to map deep scotomas in a time 
efficient manner (Wu et al., 2019a). 
5.2.2. Patient-tailored test-patterns 
Recently, patient-tailored perimetry grids have been introduced in 
the setting of FCP (MacLaren et al., 2014; Pfau et al., 2020c). In the first 
gene therapy trial for choroideremia, a rectilinear grid was modified 
through addition and removal of test-points to cover the island of 
functional retina, while keeping the overall test-duration short 
(MacLaren et al., 2014). While this allowed function to be assessed 
within a given eye over time, this procedure was not automated and did 
not consider the normative hill-of-vision to compute loss-of-function 
(rather than absolute sensitivity) for inter-eye comparisons. 
As a prerequisite for refined patient-tailored perimetry (Fig. 5), a 
method to spatially-interpolate normative data has been brought for-
ward, which allows to calculate perimetry indices independent of the 
test pattern and centration (Denniss et al., 2017; Denniss and Astle, 
2016). This now allows to analyze data from patients with “decentered 
fixed patterns” (Denniss et al., 2017; Denniss and Astle, 2016). Building 
on this, it is now possible to generate and evaluate patient-tailored 
perimetry patterns based on multimodal imaging data in an auto-
mated manner. Hereby, the goal is to maximize the density of test-points 
in disease relevant regions of interest (e.g., junctional zone in eyes with 
GA), while minimizing the number of test-point in uninformative re-
gions (e.g., area of atrophy lesion in eyes with GA) (Fig. 5). This 
fundamental principle of using imaging data to automatically generate 
patient-tailored patterns could of course be extended to other retinal 
diseases to measure the progression of well-demarcated boundaries (e. 
g., late-onset Stargardt disease) (Pfau et al., 2020c). An inherent 
downside of patient-tailored perimetry is that distant regions are not 
monitored – however, these may eventually show disease progression as 
well (i.e., de novo foci of atrophy). 
5.3. Analysis of sensitivity data, statistical considerations for clinical trial 
planning 
The approach for the analysis of FCP sensitivity results in clinical 
trials can benefit from consideration of how visual field sensitivity data 
is analyzed more broadly. The first consideration is whether this 
outcome is analyzed at the individual level (i.e. comparing the differ-
ence in how many eyes demonstrate visual function progression based 
on a specific criteria), or at the population level (i.e. examining whether 
the overall change in outcome measure over time differs between 
different intervention groups). In order to be accepted as an outcome 
measure, the analysis method must be accepted by the regulatory au-
thority and be able to be applied across international multiple sites. The 
complexity of any analysis methodology must be balanced with the 
validity of the measurement for what is being measured and ability to 
pick up relevant changes in the retinal sensitivity. 
5.3.1. Analysis at the individual level 
For detection of progression at the individual level, there are typi-
cally four approaches taken: event-based vs. trend-based analysis, at a 
global- or point-wise level (Vianna and Chauhan, 2015). The two most 
common methods used is point-wise event-based analysis (based on a 
number of tested locations showing deterioration exceeding test-retest 
limits on several consecutive tests from baseline) or global trend-based 
analysis (slope of change significantly exceeding zero or age-expected 
changes). 
However, one recent study showed that rigorously-matched com-
parisons of the point-wise event- and global trend-based analysis actu-
ally had similar performance overall in glaucoma eyes, but there was 
only a moderate level of agreement between the two methods (Wu and 
Medeiros, 2018a). This suggests that both methods are likely useful at 
capturing localized and global changes in visual sensitivity, and both 
should be considered. 
A previous study demonstrated that the use of Bayesian models, 
which allow the results from point-wise event-based analysis to influ-
ence the inference of the trend-based analysis (i.e., combining the two 
Fig. 5. Patient-tailored perimetry.  
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approaches), can improve the ability to detect progression that using 
either method alone (Medeiros et al., 2012). This notion of using both 
sources of information for detecting progression can also be exploited by 
using artificial intelligence-based methods. A recent study demonstrated 
that this method performs better than using either methods alone 
(Yousefi et al., 2018). 
Nonetheless, these novel approaches would require robust develop-
ment and validation when applied to analysis of FCP sensitivity data in 
clinical trials before they can gain acceptance. Conventional point-wise 
event-based or global trend-based analyses would thus currently be 
preferable, and especially the latter given the current lack of robustly 
validated methods for pointwise event-based analyses and the similarity 
of the performance of these two approaches. For such analyses, data 
should be acquired using the follow-up mode to ensure that the same 
location is probed across all visits. Indeed, regulatory authorities such as 
the Food and Drug Administration (FDA) in the United States accepts 
analyses of visual field endpoints in glaucoma based on either of these 
two approaches (Weinreb and Kaufman, 2009). Point-wise changes may 
also be lacking in robustness until the fundus-tracking rate is improved 
(see discussion in 2.5.1). 
5.3.2. Analysis at the population level 
While analyses of progression at the individual level in clinical trials 
is beneficial because it provides a meaningful assessment of treatment 
efficacy at the person-level, this is achieved at a substantial cost to the 
power to detect treatment effects. 
One recent study demonstrated that an approximately seven to ten 
fold reduction in sample size requirements could be achieved by eval-
uating the difference in rate of change in visual function between 
groups, as compared to evaluating the difference in the number of eyes 
that showed progression at the individual level based on point-wise 
event-based analysis, since the latter does not make full use of all the 
data available over the entire follow-up duration (Wu et al., 2019b). As 
such, this approach has been used increasingly for analyzing FCP data in 
clinical trials (Chew et al., 2019; Heier et al., 2020; Wu et al., 2019c). 
5.3.3. Other considerations in clinical trials 
In addition to the approach for analysis of the FCP sensitivity data, 
considerations about other aspects of the trial design could improve the 
power to detect change over time for this outcome measure. 
The design of the clinical trial follow-up paradigm will also play an 
important role in the power to detect differences between group for the 
outcome measure of FCP sensitivity. Based on previous suggestions that 
a clustered testing paradigm (i.e. more tests at the bookends of the trial 
follow-up period) could improve detection of progression at the indi-
vidual level (Crabb and Garway-Heath, 2012), a modification to the 
traditional evenly-spaced testing paradigm was made to a landmark 
clinical trial in glaucoma (Garway-Heath et al., 2015). One recent study 
showed that this strategy indeed improves the power to detect differ-
ences in visual field outcomes in clinical trials, and the power increases 
the more tests are included at the bookends of the follow-up period (Wu 
and Medeiros, 2018b). 
5.3.4. Strategies used in clinical trials to date 
A variety of outcome measures are currently reported for interven-
tional trials. The change in mean sensitivity over time has been applied 
in the context of the choroideremia gene therapy trials (Xue et al., 
2018). For retinal diseases with central RPE-atrophy such as geographic 
atrophy or Stargardt disease, variegated measures have been proposed 
including change in mean sensitivity (Meleth et al., 2011; Schönbach 
et al., 2017), or change in the number or percentage of scotomatous loci 
(Meleth et al., 2011; Pilotto et al., 2013; Wu et al., 2019a). More com-
plex analyses have also been proposed. This includes classification of 
test-points as dense scotoma, edge of the scotoma loci and remaining 
loci based on baseline sensitivity and then computing sensitivity 
changes for these regions separately (Chen et al., 2011). This selective 
analysis of test-points at the edge of the scotomas was recently shown to 
be much more responsive to disease progression for patients with Star-
gardt disease (Etienne M. Schönbach et al., 2020b) as well as for patients 
with USH2A retinopathy (Charng et al., 2020a). 
Moreover, topographic modeling has been recently applied in the 
setting of SAP and FCP to derive volumetric visual indices as outcome 
measure for clinical trials (Josan et al., 2020; Parker et al., 2016; 
Weleber et al., 2015) (NCT00749957, NCT01233609). 
5.3.5. Additional strategies developed 
In addition to the measures of central tendency (mean sensitivity, 
mean defect, mean deviation), measures of visual field irregularity (loss 
variance, pattern standard deviation) are established in the context of 
SAP. To date, this is not mirrored in commercially-available FCP de-
vices, with the exception of the COMPASS device (Rossetti et al., 2015), 
and the local defect map provided by the MP-1 device. Typically, 
sensitivity is shown at each location tested using a color coding that does 
not take into account patient age or the eccentricity. Both of these are 
factors that affect what can be considered normal (Cassels et al., 2019; 
Charng et al., 2020b; Pfau et al., 2018b). Pattern deviation can be 
calculated for FCP data based on normative data derived through 
bootstrapping and/or geospatial statistical techniques (Cassels et al., 
2019; Denniss and Astle, 2016; Pfau et al., 2018b). In eyes with signif-
icant overall sensitivity loss (or total deviation), spatially-resolved 
mapping of pattern deviation is helpful to delineate scotoma bound-
aries (Denniss et al., 2017). 
Moreover, innovative approaches that take into account the test- 
retest variability and complex relationships among test-points using 
compute vision techniques may further increase the sensitivity to 
localized changes in the visual field (Alexander et al., 2012; Wilson 
et al., 2018). 
5.4. FCP and structure function correlation 
5.4.1. Overarching aim of structure function correlation 
Structure function correlation typically serves two fundamental 
purposes: (1) establishment of the concurrent validity between func-
tional biomarkers and expert-based classifications (i.e., Clinician- 
Reported Outcome Assessments [ClinROs]) or native (anatomical) im-
aging biomarkers, or (2) to document structure function dissociation. 
The former (establishment structure function correlation) constitutes an 
important factor for the acceptance of a PerfO by regulatory agencies. 
Evidence of structure function dissociation can be helpful (2.1) to 
identify a target for therapeutic intervention, (2.2) as early marker of 
disease progression and (2.3) as indicator of unanticipated/adverse 
treatment effects. 
Many of the currently used structural biomarkers such as the quan-
tification of RPE-atrophy in eyes with GA are supported by FCP in terms 
of concurrent validity (Meleth et al., 2011; Schmitz-Valckenberg et al., 
2004). Many other biomarkers that are currently quantified in larger 
trials have also been previously validated using FCP including the cen-
tral area of residual ellipsoid zone (EZ) presence in RP (Greenstein et al., 
2012; Hood et al., 2011), or loss of EZ in MacTel type 2 (Sallo et al., 
2012), as well as the integrity of the inner segments and EZ and retinal 
pigment epithelium-drusen complex (RPEDC) thickness in intermediate 
AMD (Pfau et al., 2018a; Wu et al., 2014). 
Documentation of structure function dissociation serves a three-fold 
purpose: 
1. First, structure function dissociation may allow us to identify 
diseases that are amenable to vision improvement as recently reviewed 
in detail by Garafalo et al. in the context of inherited retinal diseases and 
gene therapy (Garafalo et al., 2020). Briefly, some inherited retinal 
diseases, including Leber congenital amaurosis (LCA) caused by RPE65 
mutations, exhibited markedly reduced function despite of a relatively 
preserved retinal architecture. This structure function dissociation be-
comes apparent when comparing structural data from RPE65-LCA 
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patients with structural data from RP patients. The latter patients exhibit 
in relative terms markedly better visual function (Cideciyan et al., 
2008). By extensions, supervised models, which were trained to predict 
light sensitivity based on SD-OCT structure in RP patients, may be 
applied to structural data of RPE65-LCA patients to infer the maximum 
vision improvement potential through gene therapy in these patients 
(Sumaroka et al., 2019). 
2. Second, structure function dissociation may be exploited to 
improve diagnostic sensitivity and to obtain a more sensitive measures 
of diseases progression (Medeiros, 2017; Montesano et al., 2020). 
Especially in the setting of SAP and glaucoma, multiple studies support 
the application of composite endpoints of functional and imaging bio-
markers to overcome the weaknesses of these endpoints in isolation 
(Lisboa et al., 2013; Medeiros, 2017; Wu and Medeiros, 2019). 
3. Third, structure function dissociation may help to identify unan-
ticipated/adverse treatment effects. Moreover, close structure function 
association in a natural-history setting may be dissociated in the context 
of a treatment that preserve tissue anatomy without equally preserving 
function (Medeiros, 2017). For example, intravitreal injections of 0.1 ml 
(as used in a recent trial investigating an antibody directed against 
complement factor D in GA) led frequently to post-injection increases of 
the intraocular pressure (Holz et al., 2018). While the inner retinal 
thickness and reflectivity was shown to be of little relevance for the 
prediction of retinal sensitivity in un-treated patients with GA (Pfau 
et al., 2020a), this assumption may not necessarily extend to patients 
with previous post-injection increase of the intraocular pressure. Hence, 
development of surrogate endpoints requires initially conducting a trial 
with a given treatment while analyzing the surrogate and true endpoint 
(Medeiros, 2017). 
5.4.2. Technical considerations 
For structure function correlation, the image registration and the 
statistical analysis can markedly affect the results. Importantly, struc-
ture function correlation (without image registration) based on stimulus 
coordinates may lead to erroneous results in presence of obvious 
eccentric fixation and grid displacement, as well as in patients with 
subtle eccentric fixation (Mallery et al., 2016). 
While early reports used rather simple strategies for obtaining 
structural biomarkers (e.g., for ETDRS subfields (Roh et al., 2019)), it is 
preferable to conduct structure function analyses in a precise, point-wise 
manner. This necessitates to register the FCP data to the structural data 
based on multiple vessel bifurcations (≥4) using ‘nonrigid’ trans-
formations to compensate for differences in field-of-view, head/-
eye-rotation in the sagittal, coronal and transverse planes. Subsequently, 
thickness and reflectivity values may be extracted corresponding to the 
precise stimulus location (Pfau et al., 2018a). For the Heidelberg Spec-
tralis device it is important to note, that the co-acquired IR image and 
SD-OCT volume may be minimally offset (Barteselli et al., 2013). 
Accordingly, the FCP data should be (whenever possible) registered to 
the actual SD-OCT volume using an en-face SD-OCT image rather than to 
the IR image (Fig. 6). Besides of custom workflows using ImageJ (In-
stitutes of Health, Bethesda, Maryland, USA [described for example in 
the supplement of (Pfau et al., 2020a)]), NIDEK offers a software solu-
tion enabling co-registration of MP-3 data with OCT data (from the 
NIDEK RS-3000 Advance OCT) to extract layer thickness data for each 
stimulus (Funatsu et al., 2019). 
For disease of the inner retina (glaucoma and other ganglion cell 
disorders), layer thicknesses and reflectivity values should be extracted 
for the inner retina with consideration of the displacement of retinal 
ganglion cell (RGC) from their receptive fields. Multiple models for this 
displacement, which may be applied across patients for structure func-
tion correlation, have been published (Drasdo et al., 2007; Sjöstrand 
et al., 1999; Watson, 2014). In addition, individualized displacement 
models taking into account SD-OCT parameters have been previously 
used for structure function correlation in the setting of SAP and glau-
coma (Turpin et al., 2015). 
For the inferential statistical analyses (i.e., “calculating P-values”), 
models applicable to repeated measurements such as linear mixed 
models should be applied (Wu et al., 2016a). The independent unit of 
observation are patients. Accordingly, simple linear regression analyses 
or correlation analyses across individual test-points (as unfortunately 
commonly reported) will lead to incorrectly low P-values (Lazic, 2010). 
Similarly, in the setting of more complex models such as machine- 
learning and deep-learning models, cross-validated accuracy estimates 
should be reported for patient-wise cross-validation, since patient- 
specific information will markedly increase prediction accuracies 
(Kihara et al., 2019; Pfau et al., 2020a; von der Emde et al., 2019a). 
Moreover, estimates such as the mean absolute error (MAE) and 
root-mean-squared error (RMSE) between sensitivity prediction and FCP 
measurement and Bland-Altman plots should be provided to allow for 
assessment of the model accuracy. The coefficient-of-determination (R2) 
tends to be difficult to compare across studies since it is markedly 
Fig. 6. Structure function correlation.  
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dependent on the underlying dispersion of the data (i.e., study 
population). 
Last, it is often advantageous to standardize structural SD-OCT data 
from patients as z-scores using test-point-specific normative data with 
regard to interpretability (Pfau et al., 2020a; von der Emde et al., 
2019a). Otherwise, trivial association may mask disease-specific struc-
ture function correlations. For example, non-standardized nerve fiber 
layer thickness, which is essentially an indicator of eccentricity, may 
carry a paradoxically high feature importance in outer retinal diseases, 
which disappears, once the structural data is standardized. 
6. Future directions and conclusions 
Tremendous progress has been made since the introduction of the 
first commercially-available FCP device thirty years ago. However, FCP 
does not yet constitute a routine clinical examination or outcome mea-
sure to date. A variety of challenges and unmet needs provides the op-
portunity for further research in this area: 
1. Psychometric evaluation in a disease- and device-specific manner 
is lacking for many diseases. While studies reporting concurrent validity 
in terms of structure function correlation are common, future research 
will need to address the magnitude of intra-session versus inter-session 
test-retest reliability, the effect of the test administrator and auditory 
feedback on test-results, inter-device reliability and content validity (e. 
g., against full-field threshold testing), discriminant validity (i.e., dis-
ease stages) and predictive validity. Regulatory agencies have stated 
their preference for functional outcome measures that relate to orien-
tation and mobility, daily living in patients’ home environments, and 
occupational needs such as reading (Csaky et al., 2017; Jolly et al., 
2019). This warrants the assessment of concurrent validity beyond 
structure function correlation. An example for an ongoing 
natural-history study evaluating specifically these aspects is the 
EU-funded MACUSTAR study for AMD (Finger et al., 2019), and the 
NEI-funded ARIS. 
2. Multiple developments in the area of standard automated peri-
metry have not been translated to FCP. These include time-saving 
threshold estimation strategies such as SITA, ZEST, GATE (COMPASS 
device provides ZEST), which would facilitate a more widespread 
adoption of FCP (Turpin et al., 2003). Other examples are the inclusion 
of pre-adaptation (i.e., dark adaptation) and chromatic perimetry for 
photoreceptor-specific testing as well as stimulus-presentation tech-
niques to isolate post-receptoral mechanisms. Maximization of photo-
receptor and post-receptoral pathway isolation is a prerequisite for 
hypothesis-based testing of therapeutic efficiency (Simunovic et al., 
2016). These approaches are for example needed to differentiate be-
tween minimal degrees of cone function from rod intrusion in gene 
therapy trials for primary cone diseases (e.g., achromatopsia, blue-cone 
monochromacy) (Thompson et al., 2020). 
3. Statistical methods to summarize FCP could be refined and stan-
dardized. For example techniques such as spatial-interpolation could be 
used to obtain unweighted perimetry indices for radial test pattern 
(Denniss and Astle, 2016; Weleber et al., 2015). Moreover, 
variability-weighted indices (as used in the context of standard auto-
mated perimetry) and point-wise analysis may be more sensitive to 
functional loss over time (Pfau et al., 2018b; Wu et al., 2016a). 
4. The application of parameter-rich models (“artificial intelli-
gence”), including convolution neural networks and random forest 
regression, has recently allowed multiple groups to drastically increase 
the accuracy of structure function correlation in the context of macular 
telangiectasia type 2 (Kihara et al., 2019), Leber congenital amaurosis 
(Sumaroka et al., 2019), neovascular AMD (von der Emde et al., 2019a) 
and geographic atrophy (Pfau et al., 2020a). This facilitates en face 
mapping of “inferred sensitivity” with a spatial resolution and retinal 
coverage beyond the possibilities of psychophysical testing (Pfau et al., 
2020a). Extension to further diseases and software solutions for routine 
clinical practice and clinical trials will be needed. 
5. Adaptive-optic (AO) FCP allows for true “microperimetry” with 
single photoreceptor stimulation (Reiniger et al., 2017). While the 
utility of dissecting function at a cellular level for basic research is 
obvious, applicable clinical trial protocols for AO FCP are lacking. To 
date, it is unclear whether the advantage in resolution of AO FCP truly 
translates to an improved ability to detect change, which also depends of 
the dynamic range of stimuli and retinal area investigated. However, 
recent developments may allow for a much greater dynamic range for 
AO-based perimetry devices (Domdei et al., 2018). 
6. Standardization for testing (test-pattern, staircase strategy, adap-
tation, pupil dilatation), criteria for test repetition as well as reporting 
standards are lacking. A well-established example for this type of stan-
dardization in the setting of retinal electrophysiology are the guidelines 
by the International Society for Clinical Electrophysiology of Vision 
(Robson et al., 2018). 
In summary, we advocate for the application of FCP as an important 
functional outcome measure for clinical trials. Herein, we provided best- 
practice recommendations regarding the test-setting and test-pattern. 
However, prior to the application in clinical trials, natural history 
studies should underscore the reliability, validity and ability-to-detect- 
change in a disease-, stage- and device-specific manner. An overview 
of diseases in which FCP has been (substantially) validated is provided. 
The selection of the test-pattern and background illumination should be 
reflective of the topographic progression of the disease and its hypoth-
esized effect on retinal photoreceptors (Fig. 7). Moreover, the statistical 
analysis strategy and follow-up protocol should be selected in accor-
dance of the expected treatment effect (global vs. local, slowing of dis-
ease progression vs. improvement of vision). 
Panel A. Commercially-available fundus-controlled perimetry (FCP) 
devices (“microperimeters”) feature three core components. The stim-
ulus and background projection unit employs typically a liquid crystal 
display (LCD) or a combination of light emitting diodes (LEDs). The 
imaging unit, which is typically based on an infrared scanning (IR) laser 
ophthalmoscope (SLO) or IR fundus-camera, simultaneously images the 
fundus. This imaging is used to track the retina based on landmarks (e.g., 
vessel bifurcations) in order to adjust the stimulus position or pause the 
stimulus presentation in moments of fixation instability. 
Panel B. The background has a marked influence of the measure 
photoreceptor function. The first and second generation of devices 
typically project a mesopic background (1.27 cd/m2, approximately 
luminance level of “scene lit by full moon”). The resulting redundancy in 
stimulus detection may impede detection of minor degrees of isolated 
rod or cone function loss(Simunovic et al., 2016). More recent devices 
allow for isolated testing of rod function (scotopic background, <0.03 
cd/m2, “dark night in the new moon phase”) and cone function (phot-
opic background, 10 cd/m2, “daylight”). 
Besides mesopic testing, which results in redundancy of target 
detection (i.e., cone- and rod-mediated) (Simunovic et al., 2016), se-
lective perimetry strategies are available in the setting of 
fundus-controlled perimetry (FCP) (Pfau et al., 2017b; Remky and Els-
ner, 2005; Rohrschneider et al., 2008). 
Panel A. Dark-adapted testing with no background (i.e., scotopic 
testing) and a short-wavelength stimulus allow for selective probing of 
rod photoreceptor function with a magnitude of isolation of approxi-
mately 2.3 log units (depending on the precise stimulus wavelength). 
Panel B. Photopic testing with white stimuli (white-on-white testing 
[W-on-W]) and red stimuli (red-on-white [R-on-W]) is s L/M-cone 
mediated. Using a yellow chromatic adapting background light and 
short-wavelength stimulus (blue-on-yellow testing [B-on-Y]), S-cone 
isolation 1 to 2 log units may be achieved (varies in dependence of the 
background and stimulus wavelength) (Demirel and Johnson, 2000; 
Roman et al., 2019). The curves in the lower left panel are based on the 
dark-adapted spectral sensitivity curves (Wald, 1945), the curves in the 
lower right depict the population weighted cone sensitivity functions 
(Stockman and Sharpe, 2000). Dashed arrows highlight the degree of 
isolation for a given photoreceptor subtype and stimulus wavelength. 
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The upper row shows a healthy subject and the lower row a patient 
with choroideremia. Poor focus will result in moderately lower sensi-
tivity measurements (mean sensitivity [MS]) and impedes structure 
function correlation. Please note the absence of central vascular bi-
furcations, which could be used for multimodal image registration, in 
the eye of a patient with choroideremia. Clipping by the iris (i.e., 
decentration of the device in relation to the eye) can yield also erroneous 
results. The inlay shows the test results with a white background. For 
two test-points, no responses were recorded (i.e., sensitivity estimate of 
<0 dB). 
The panel shows typical fixed test patterns employed in clinical 
studies. The conventional rectilinear pattern provides an even sam-
pling density. Accordingly, the mean sensitivity across all test-points 
constitutes an unbiased estimate of the area examined. The here 
shown 10-2 grid is applicable across a wide range of retinal disease. 
However, given the relatively wide gaps between test-points (2◦), the 
10-2 pattern may be relatively insensitive to slow scotoma progression. 
Radial patterns are characterized by a central condensation of test- 
points. Therefore, the mean of all test-points (without correction) will 
constitute a spatially-weighted average. Radial patterns are especially 
useful to evaluate function in diseases that are confined to the fovea and 
parafovea including the patient with Chloroquine retinopathy as shown 
in this example. Profiles (i.e., most commonly the horizontal profile) are 
applicable in diseases that exhibit either a marked centrifugal or cen-
tripetal pattern of progression. Especially in retinitis pigmentosa as in 
this example using a profile test pattern, the sensitivity along the hori-
zontal meridian may be considered as a proxy of overall disease severity. 
Circular peripapillary patterns allow for monitoring of nerve fiber 
layer bundle defects as commonly observed in glaucomatous optic 
neuropathy. 
In some diseases such as geographic atrophy secondary to age- 
related macular degeneration, the topographic variability would 
require a large fixed test-pattern resulting in a burdensome test, while 
providing only limited information regarding zones of interest with 
future disease progression (i.e., junctional zone). The number of test- 
points in these regions essentially determines the ability to detect 
change. Patient-tailored perimetry allows to maximize the number of 
relevant test-points while limiting the number of overall test-points. 
Based on multimodal imaging data, areas of atrophy are annotated 
(1). An automated software can then use these annotations in conjunc-
tion with pre-defined “pattern defining rules” (2) to generate a patient- 
tailored pattern (3), which is then transferred to the device for perimetry 
testing (4). To allow for meaningful between-subject comparison of 
data, all test-points must be analyzed considering age-matched, spatially 
corresponding normal data (5). To do so, age-adjusted, interpolated 
sensitivity maps and precise landmark-based (fovea, optic nerve head) 
registration of data are prerequisites. 
For precise structure function correlation, (1) the fundus-controlled 
perimetry data should be registered to the structural data based on 
multiple vessel bifurcations (≥4) using ‘nonrigid’ transformations to 
allow to compensate for differences in field-of-view, head/eye-rotation 
in the coronal as well as axial plane. In the case of optical coherence 
tomography (OCT) data, (2) semi-automated or automated multilayer 
segmentation can be applied. In the last step (3), layer thickness and 
reflectivity values corresponding precisely to each stimulus area and 
position can be extracted. 
As highlighted throughout this manuscript, a wide range of critical 
decisions are necessary for the development of clinical trial protocols 
employing FCP. Disease-specific prior knowledge allows to narrow 
down these choices. Specifically, the disease topography and natural 
history in conjunction with the intended treatment effect (localized vs. 
global) dictate the test-pattern. For example, diseases with a rather 
consistent spatial manifestation (e.g., retinitis pigmentosa, hydroxy-
chloroquine retinopathy [HCQ-RPE]) may be monitored along the 
horizontal meridian (profile). In contrast, disease with marked topo-
graphic variability (e.g., geographic atrophy [GA]) may be monitored 
more accurately using a wide-spread rectilinear or patient-tailored 
pattern. To avoid redundancy in target detection, a selective perimetry 
strategy should be applied in consideration of the targeted receptoral or 
postreceptoral pathway. The retest reliability and expected treatment 
effect (slowing of progression vs. improvement) determine the required 
granularity of the staircase-strategy and the follow-up as well as intra- 
session retest schedule. 
Fig. 7. Clinical trial recommendations for fundus-controlled perimetry (FCP).  
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Netzhauterkrankungen. Klin. Monbl. Augenheilkd. 234, 311–319. https://doi.org/ 
10.1055/s-0043-100631. 
Remky, A., Elsner, A.E., 2005. Blue on yellow perimetry with scanning laser 
ophthalmoscopy in patients with age related macular disease. Br. J. Ophthalmol. 89, 
464–469. https://doi.org/10.1136/bjo.2004.050260. 
Remky, A., Elsner, A.E., Morandi, A.J., Beausencourt, E., Trempe, C.L., 2001. Blue-on- 
yellow perimetry with a scanning laser ophthalmoscope: small alterations in the 
central macula with aging. J. Opt. Soc. Am. A 18, 1425. https://doi.org/10.1364/ 
josaa.18.001425. 
Robson, A.G., El-Amir, A., Bailey, C., Egan, C.A., Fitzke, F.W., Webster, A.R., Bird, A.C., 
Holder, G.E., 2003. Pattern ERG correlates of abnormal fundus autofluorescence in 
patients with retinitis pigmentosa and normal visual acuity. Investig. Ophthalmol. 
Vis. Sci. 44, 3544–3550. https://doi.org/10.1167/iovs.02-1278. 
Robson, A.G., Nilsson, J., Li, S., Jalali, S., Fulton, A.B., Tormene, A.P., Holder, G.E., 
Brodie, S.E., 2018. ISCEV guide to visual electrodiagnostic procedures. Doc. 
Ophthalmol. 136, 1–26. https://doi.org/10.1007/s10633-017-9621-y. 
Roh, M., Laíns, I., Shin, H.J., Park, D.H., Mach, S., Vavvas, D.G., Kim, I.K., Miller, J.W., 
Husain, D., Miller, J.B., 2019. Microperimetry in age-related macular degeneration: 
association with macular morphology assessed by optical coherence tomography. Br. 
J. Ophthalmol. 103, 1769–1776. https://doi.org/10.1136/bjophthalmol-2018- 
313316. 
Rohrschneider, K., Becker, M., Fendrich, T., Volcker, H.E., 1995a. Kinetic fundus 
perimetry with the scanning laser ophthalmoscope. Klin. Monbl. Augenheilkd. 207, 
102–110. https://doi.org/10.1055/s-2008-1035356. 
Rohrschneider, K., Becker, M., Krastel, H., Kruse, F.E., Völcker, H.E., Fendrich, T., 1995b. 
Static fundus perimetry using the scanning laser ophthalmoscope with an automated 
threshold strategy. Graefe’s Arch. Clin. Exp. Ophthalmol. 233, 743–749. https://doi. 
org/10.1007/BF00184084. 
Rohrschneider, K., Glück, R., Becker, M., Kruse, F.E., Burk, R.O.W., Fendrich, T., 
Völcker, H.E., 1996. Automatic static fundus perimetry for precise detection of early 
glaucomatous function loss. Investig. Ophthalmol. Vis. Sci. 37, 453–462. 
Rohrschneider, K., Bültmann, S., Glück, R., Kruse, F.E., Fendrich, T., Völcker, H.E., 2000. 
Scanning laser ophthalmoscope fundus perimetry before and after laser 
photocoagulation for clinically significant diabetic macular edema. Am. J. 
Ophthalmol. 129, 27–32. https://doi.org/10.1016/S0002-9394(99)00270-6. 
Rohrschneider, K., Bültmann, S., Springer, C., 2008. Use of fundus perimetry 
(microperimetry) to quantify macular sensitivity. Prog. Retin. Eye Res. 27, 536–548. 
https://doi.org/10.1016/j.preteyeres.2008.07.003. 
Roisman, L., Ribeiro, J.C., Fechine, F.V., Lavinsky, D., Moraes, N., Campos, M., Farah, M. 
E., 2014. Does microperimetry have a prognostic value in central serous 
chorioretinopathy? Retina 34, 713–718. https://doi.org/10.1097/ 
IAE.0b013e3182a323fe. 
Roman, A.J., Powers, C.A., Semenov, E.P., Sheplock, R., Aksianiuk, V., Russell, R.C., 
Sumaroka, A., Garafalo, A.V., Cideciyan, A.V., Jacobson, S.G., 2019. Short- 
wavelength sensitive cone (S-cone) testing as an outcome measure for NR2E3 
clinical treatment trials. Int. J. Mol. Sci. 20 https://doi.org/10.3390/ijms20102497. 
Rossetti, L., Digiuni, M., Rosso, A., Riva, R., Barbaro, G., Smolek, M.K., Orzalesi, N., De 
Cilla, S., Autelitano, A., Fogagnolo, P., 2015. Compass: clinical evaluation of a new 
instrument for the diagnosis of glaucoma. PloS One 10, e0122157. https://doi.org/ 
10.1371/journal.pone.0122157. 
Sacconi, R., Casaluci, M., Borrelli, E., Mulinacci, G., Lamanna, F., Gelormini, F., 
Carnevali, A., Querques, L., Zerbini, G., Bandello, F., Querques, G., 2019. 
Multimodal imaging assessment of vascular and neurodegenerative retinal 
alterations in type 1 diabetic patients without fundoscopic signs of diabetic 
retinopathy. J. Clin. Med. 8, 1409. https://doi.org/10.3390/jcm8091409. 
M. Pfau et al.                                                                                                                                                                                                                                    
Progress in Retinal and Eye Research 82 (2021) 100907
25
Sachdev, A., Edington, M., Morjaria, R., Chong, V., 2019. Comparing microperimetric 
and structural findings in patients with branch retinal vein occlusion and diabetic 
macular edema. Retina 39, 446–451. https://doi.org/10.1097/ 
IAE.0000000000001961. 
Sallo, F.B., Peto, T., Egan, C., Wolf-Schnurrbusch, U.E.K., Clemons, T.E., Gillies, M.C., 
Pauleikhoff, D., Rubin, G.S., Chew, E.Y., Bird, A.C., Sahel, J.A., Guymer, R., 
Soubrane, G., Gaudric, A., Schwartz, S., Constable, I., Cooney, M., Egan, C., 
Singerman, L., Gillies, M.C., Friedlander, M., Pauleikhoff, D., Moisseiev, J., 
Rosen, R., Murphy, R., Holz, F., Comer, G., Blodi, B., Do, D., Brucker, A., 
Narayanan, R., Wolf, S., Rosenfeld, P., Bernstein, P.S., Miller, J.W., 2012. The IS/OS 
junction layer in the natural history of type 2 idiopathic macular telangiectasia. 
Investig. Ophthalmol. Vis. Sci. 53, 7889–7895. https://doi.org/10.1167/iovs.12- 
10765. 
Saßmannshausen, M., Steinberg, J.S., Fimmers, R., Pfau, M., Thiele, S., Fleckenstein, M., 
Holz, F.G., Schmitz-Valckenberg, S., 2018. Structure-function analysis in patients 
with intermediate age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 
59, 1599–1608. https://doi.org/10.1167/iovs.17-22712. 
Schiefer, U., Pätzold, J., Dannheim, F., 2005. Konventionelle perimetrie. Teil I: 
einführung - grundbegriffe. Ophthalmologe 102, 627–646. https://doi.org/10.1007/ 
s00347-005-1189-3. 
Schmidt-Erfurth, U.M., Michels, S., 2003. Changes in confocal indocyanine green 
angiography through two years after photodynamic therapy with verteporfin. 
Ophthalmology 110, 1306–1314. https://doi.org/10.1016/S0161-6420(03)00452- 
4. 
Schmitz-Valckenberg, S., Bültmann, S., Dreyhaupt, J., Bindewald, A., Holz, F.G., 
Rohrschneider, K., 2004. Fundus autofluorescence and fundus perimetry in the 
junctional zone of geographic atrophy in patients with age-related macular 
degeneration. Investig. Ophthalmol. Vis. Sci. 45, 4470–4476. https://doi.org/ 
10.1167/iovs.03-1311. 
Schmitz-Valckenberg, S., Fan, K., Nugent, A., Rubin, G.S., Peto, T., Tufail, A., Egan, C., 
Bird, A.C., Fitzke, F.W., 2008. Correlation of functional impairment and 
morphological alterations in patients with group 2A idiopathic juxtafoveal retinal 
telangiectasia. Arch. Ophthalmol. 126, 330–335. https://doi.org/10.1001/ 
archopht.126.3.330. 
Schmitz-Valckenberg, S., Ong, E.L., Rubin, G.S., Peto, T., Tufail, A., Egan, C.A., Bird, A. 
C., Fitzke, F.W., 2009. Structural and functional changes over time in mactel 
patients. Retina 29, 1314–1320. https://doi.org/10.1097/IAE.0b013e3181a4d2f1. 
Scholl, H.P.N., Bellmann, C., Dandekar, S.S., Bird, A.C., Fitzke, F.W., 2004. Photopic and 
scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in 
patients with age-related maculopathy. Investig. Ophthalmol. Vis. Sci. 45, 574–583. 
https://doi.org/10.1167/iovs.03-0495. 
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Schönbach, Etienne M., Strauss, R.W., Ibrahim, M.A., Janes, J.L., Birch, D.G., 
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